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A B S T R A C T
Background
Insulin requirements may change during pregnancy, and the optimal treatment for pre-existing diabetes is unclear. There are several
insulin regimens (e.g. via syringe, pen) and types of insulin (e.g. fast-acting insulin, human insulin).
Objectives
To assess the effects of different insulin types and different insulin regimens in pregnant women with pre-existing type 1 or type 2
diabetes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 October 2016), ClinicalTrials.gov (17 October 2016),
the WHO International Clinical Trials Registry Platform (ICTRP; 17 October 2016), and the reference lists of retrieved studies.
Selection criteria
We included randomised controlled trials (RCTs) that compared different insulin types and regimens in pregnant women with pre-
existing diabetes.
We had planned to include cluster-RCTs, but none were identified.We excluded quasi-randomised controlled trials and cross-over trials.
We included studies published in abstract form and contacted the authors for further details when applicable. Conference abstracts
were superseded by full publications.
Data collection and analysis
Two review authors independently assessed trials for inclusion, conducted data extraction, assessed risk of bias, and checked for accuracy.
We assessed the quality of the evidence using the GRADE approach.
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Main results
The findings in this review were based on very low-quality evidence, from single, small sample sized trial estimates, with wide confidence
intervals (CI), some of which crossed the line of no effect; many of the prespecified outcomes were not reported. Therefore, they should
be interpreted with caution. We included five trials that included 554 women and babies (four open-label, multi-centre, two-arm trials;
one single centre, four-arm RCT). All five trials were at a high or unclear risk of bias due to lack of blinding, unclear methods of
randomisation, and selective reporting of outcomes. Pooling of data from the trials was not possible, as each trial looked at a different
comparison.
1. One trial (N = 33 women) compared Lispro insulin with regular insulin and provided very low-quality evidence for the outcomes.
There were seven episodes of pre-eclampsia in the Lispro group and nine in the regular insulin group, with no clear difference between
the two groups (risk ratio (RR) 0.68, 95% CI 0.35 to 1.30). There were five caesarean sections in the Lispro group and nine in the
regular insulin group, with no clear difference between the two groups (RR 0.59, 95% CI 0.25 to 1.39). There were no cases of fetal
anomaly in the Lispro group and one in the regular insulin group, with no clear difference between the groups (RR 0.35, 95% CI
0.02 to 8.08). Macrosomia, perinatal deaths, episodes of birth trauma including shoulder dystocia, nerve palsy, and fracture, and the
composite outcome measure of neonatal morbidity were not reported.
2. One trial (N = 42 women) compared human insulin to animal insulin, and provided very low-quality evidence for the outcomes.
There were no cases of macrosomia in the human insulin group and two in the animal insulin group, with no clear difference between
the groups (RR 0.22, 95% CI 0.01 to 4.30). Perinatal death, pre-eclampsia, caesarean section, fetal anomaly, birth trauma including
shoulder dystocia, nerve palsy and fracture and the composite outcome measure of neonatal morbidity were not reported.
3. One trial (N = 93 women) compared pre-mixed insulin (70 NPH/30 REG) to self-mixed, split-dose insulin and provided very low-
quality evidence to support the outcomes. Two cases of macrosomia were reported in the pre-mixed insulin group and four in the self-
mixed insulin group, with no clear difference between the two groups (RR 0.49, 95% CI 0.09 to 2.54). There were seven cases of
caesarean section (for cephalo-pelvic disproportion) in the pre-mixed insulin group and 12 in the self-mixed insulin group, with no
clear difference between groups (RR 0.57, 95% CI 0.25 to 1.32). Perinatal death, pre-eclampsia, fetal anomaly, birth trauma including
shoulder dystocia, nerve palsy, or fracture and the composite outcome measure of neonatal morbidity were not reported.
4. In the same trial (N = 93 women), insulin injected with a Novolin pen was compared to insulin injected with a conventional needle
(syringe), which provided very low-quality evidence to support the outcomes. There was one case of macrosomia in the pen group
and five in the needle group, with no clear difference between the different insulin regimens (RR 0.21, 95% CI 0.03 to 1.76). There
were five deliveries by caesarean section in the pen group compared with 14 in the needle group; women were less likely to deliver via
caesarean section when insulin was injected with a pen compared to a conventional needle (RR 0.38, 95% CI 0.15 to 0.97). Perinatal
death, pre-eclampsia, fetal anomaly, birth trauma including shoulder dystocia, nerve palsy, or fracture, and the composite outcome
measure of neonatal morbidity were not reported.
5. One trial (N = 223 women) comparing insulin Aspart with human insulin reported none of the review’s primary outcomes:
macrosomia, perinatal death, pre-eclampsia, caesarean section, fetal anomaly, birth trauma including shoulder dystocia. nerve palsy, or
fracture, or the composite outcome measure of neonatal morbidity.
6. One trial (N = 162 women) compared insulin Detemir with NPH insulin, and supported the outcomes with very low-quality
evidence. There were three cases of major fetal anomalies in the insulin Detemir group and one in the NPH insulin group, with no
clear difference between the groups (RR 3.15, 95% CI 0.33 to 29.67). Macrosomia, perinatal death, pre-eclampsia, caesarean section,
birth trauma including shoulder dystocia, nerve palsy, or fracture and the composite outcome of neonatal morbidity were not reported.
Authors’ conclusions
With limited evidence and no meta-analyses, as each trial looked at a different comparison, no firm conclusions could be made about
different insulin types and regimens in pregnant womenwith pre-existing type 1 or 2 diabetes. Further research is warranted to determine
who has an increased risk of adverse pregnancy outcome. This would include larger trials, incorporating adequate randomisation and
blinding, and key outcomes that include macrosomia, pregnancy loss, pre-eclampsia, caesarean section, fetal anomalies, and birth
trauma.
P L A I N L A N G U A G E S U M M A R Y
What is the best insulin type and regimen for pregnant women with pre-existing diabetes?
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What is the issue?
The insulin needs of pregnant women with type 1 or 2 diabetes change during pregnancy. Insulin is available in many forms, which
affect how often and when the insulin is given. These forms vary in the time needed before the insulin has its effect, how long the effect
may last, and whether it is made from animals or humans, which may be important personally or culturally. This review looked at the
safest and most effective types and ways of giving insulin during pregnancy.
Why is this important?
Women with type 1 or 2 diabetes are at increased risk of complications during pregnancy and birth. They are more likely to experience
pregnancy loss (stillbirth, miscarriage), high blood pressure and pre-eclampsia (high blood pressure associated with swelling and protein
in the urine), and have large babies (called macrosomia, when the baby is 4 kg or more at birth) that result in injury to the mother or
baby. The likelihood of having a caesarean is increased. Mothers and babies may have complications related to managing blood glucose
levels. The baby is more likely to become overweight and develop type 2 diabetes. We wanted to find out the best type of insulin and
regimen to use during pregnancy.
What evidence did we find?
We found five randomised trials (N = 554 women and 554 babies) in October 2016. Each trial looked at different insulin types and
ways of giving the insulin. Different outcomes were looked at in each trial. One trial did not include any of the review’s main outcomes.
All five trials were small, and at a high or unclear risk of bias because of limitations in how the trials were conducted. The quality of
the evidence was very low.
When rapid-acting human insulin (Lispro) was compared to regular insulin (N = 33), investigators found no clear differences between
the groups for pre-eclampsia, abnormalities in the baby, or the need for a caesarean. Macrosomia, perinatal death, birth trauma including
shoulder dystocia, nerve palsy, and fracture, and the composite measure of neonatal morbidity were not reported.
One trial (N = 43) that compared human insulin to animal insulin did not show any clear difference in the number of babies with
macrosomia. Perinatal death, pre-eclampsia, caesarean section, fetal anomaly, birth trauma including shoulder dystocia, nerve palsy,
and fracture, and the composite measure of neonatal morbidity were not reported.
One trial (N =93) found no clear differences between pre-mixed and self-mixed insulin groups in the number of babies withmacrosomia,
and the number of women who had a caesarean section. This trial also compared insulin injected with a pen and a needle (syringe).
Women in the insulin pen group were less likely to have a caesarean section, although the number of macrosomic babies was not clearly
different. Perinatal death, pre-eclampsia, fetal anomaly, birth trauma including shoulder dystocia, nerve palsy, and fracture, and the
composite measure of neonatal morbidity were not reported.
One trial (N = 223) comparing insulin Aspart to human insulin did not include any of the review’s primary outcomes (macrosomia,
perinatal death, pre-eclampsia, caesarean section, fetal anomaly, birth trauma including shoulder dystocia, nerve palsy, and fracture, or
the composite measure of neonatal morbidity).
One trial (N = 162), which compared long-acting insulin Detemir with the intermediate-acting neutral protamine Hagedorn (NPH)
insulin found the number of fetal abnormalities was not clearly different between groups. The trial did not measure macrosomia,
perinatal death, pre-eclampsia, caesarean section, birth trauma including shoulder dystocia, nerve palsy, and fracture, or the composite
outcome measure of neonatal morbidity.
What does this mean?
The trials did not provide sufficient evidence to identify clear differences between the various insulin types and regimens. Each study
looked at a different type of insulin or regimen, so we could not combine the results. The studies were small, with overall high risk of
bias. Therefore, we could not conclude which insulin type or regimen was best for pregnant women with pre-existing diabetes. More
research is needed with larger groups of women, better reporting of how the trials were conducted, and more reported outcomes.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Patient or population: pregnant women with pre-exist ing diabetes
Setting: f our centres in Sweden. The Departments of Obstetrics and Gynaecology in Huddinge Hospital, Karolinska Hospital, Södersjukhuset in Stockholm, and Örebro Regional
Hospital
Intervention: Lispro
Comparison: regular insulin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with regular in-
sulin
Risk with Lispro
Macrosomia (0 studies) Not reported
Perinatal death Study populat ion not est imable 33
(1 RCT)
⊕©©©
VERY LOW 1,2,3
0 per 1000 0 per 1000
(0 to 0)
Pre-eclampsia Study populat ion RR 0.68
(0.35 to 1.30)
33
(1 RCT)
⊕©©©
VERY LOW 1,3,4,5
647 per 1000 440 per 1000
(226 to 841)
Caesarean sect ion Study populat ion RR 0.59
(0.25 to 1.39)
33
(1 RCT)
⊕©©©
VERY LOW 1,3,4,5
529 per 1000 312 per 1000
(132 to 736)
Fetal anomaly Study populat ion RR 0.35
(0.02 to 8.08)
33
(1 RCT)
⊕©©©
VERY LOW 1,3,4,5
59 per 1000 21 per 1000
(1 to 475)
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Birth trauma, includ-
ing shoulder dystocia,
nerve palsy, and f rac-
ture
Study populat ion Not est imable 33
(1 RCT)
⊕©©©
VERY LOW 1,2,3
0 per 1000 0 per 1000
(0 to 0)
Composite outcome
measure of neonatal
morbidity
(0 studies) Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 High or unclear risk of bias for allocat ion concealment, blinding of part icipants and personnel, blinding of outcome
assessment, incomplete outcome data, select ive outcome report ing, and other biases
2 Small sample size and no events
3 One study with design lim itat ions
4 Very wide 95% conf idence intervals crossing the line of no ef fect
5 Small sample size with few events
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B A C K G R O U N D
Description of the condition
Diabetes mellitus
The term (DM) describes a metabolic disorder of multiple aetiol-
ogy, characterised by chronic hyperglycaemia with disturbances of
carbohydrate, fat, and proteinmetabolism that results fromdefects
in insulin secretion, insulin action, or both (WHO 1999). Dia-
betesmellitus can occur during pregnancy in two forms, pre-gesta-
tional diabetes mellitus and gestational diabetes mellitus (GDM;
Daflapurkar 2014). Pre-gestational diabetes refers to type 1 or type
2 diabetes and is diagnosed before conception. Historically, type
1 diabetes was considered a disorder of children and adolescents,
generally occurring early in life, with a sudden onset of insulin
deficiency. Age at onset of diagnosis is no longer a restricting factor
(Atkinson 2014). Type 2 diabetes has been largely attributed to in-
creasing obesity and socioeconomic status (Kothari 2014; Morton
2014). Gestational diabetes mellitus is a carbohydrate intolerance
that results in hyperglycaemia (an excess of sugar in the blood) of
variable severity, with onset or first recognition during pregnancy.
It does not exclude the possibility that the glucose intolerance may
antedate pregnancy but has been previously unrecognised. The
definition applies regardless of whether or not insulin is used for
treatment, or the condition persists after pregnancy (WHO 1999).
This review will only include women with pre-existing DM (type
1 or 2).
Pathophysiology
Diabetes mellitus can be defined as abnormal glucose metabolism
due to lack of, or relatively low, insulin production. It results in
elevation of blood glucose levels with effects on all the vital or-
gans. Type 1 DM describes a condition in which the pancreas is
no longer able to produce sufficient insulin due to the destruc-
tion of the beta cells by an autoimmune process. According to the
World Health Organization (WHO) definition, type 1 DM “in-
cludes those cases attributable to an autoimmune process, as well
as those with beta-cell destruction, which are prone to ketoacidosis
for which neither an aetiology nor a pathogenesis is known (idio-
pathic). It does not include those forms of beta-cell destruction or
failure to which specific causes can be assigned (e.g. cystic fibrosis,
mitochondrial defects, etc.)” (WHO 1999). Type 2 DM includes
the common major form of diabetes that results from defects in
insulin secretion, almost always with a major contribution from
insulin resistance (Nolan 2011; WHO 1999).
Epidemiology
Diabetes mellitus is increasing globally and the number of adults
with diabetes has more than doubled over nearly three decades,
driven by both population growth and ageing, as well as the
increasing levels of overweight and obesity (Danaei 2011). In
Canada, the percentage of pregnant women with pre-existing DM
rose from 0.7% to 1.5% between 1996 and 2010 (Feig 2014).
Similar increasing trends of DM in pregnant women have been
reported in the United States (Albrecht 2010; Lawrence 2008),
and the United Kingdom (Bell 2008). Type 2 diabetes accounts
for approximately 85% to 90% of all cases of diabetes in Euro-
pean countries, and is the driving force behind increasing dia-
betes rates (Wass 2011). Furthermore, DM is the most common
pre-existing medical condition complicating pregnancy; the out-
come for diabetic pregnancy remains poor, despite improvements
in care (Kumareswaran 2013). Pre-existing DM complicates ap-
proximately 1.3% of pregnancies, one-third of these are type 1
DM, the remaining two thirds are type 2 DM (Bell 2008; Feghali
2012).
Risk factors associated with DM
Although the exact causes of type 1 DM are unknown, factors
that may signal an increased risk include the following (Daneman
2006).
• Family history (risk increases if a parent or sibling has type
1 DM).
• Environmental factors (circumstances such as exposure to a
viral illness likely play some role in type 1 DM).
• The presence of damaging immune system cells
(autoantibodies). Sometimes family members of people with
type 1 DM are tested for the presence of diabetes autoantibodies.
The presence of these antibodies is associated with an increased
risk of developing type 1 DM, but not everyone who has these
autoantibodies develops DM.
• Dietary factors (including low vitamin D consumption,
early exposure to cow’s milk or cow’s milk formula, and exposure
to cereals before four months of age. None of these factors has
been shown to directly cause type 1 DM).
• Geography. Certain countries, such as Finland and Sweden,
have higher rates of type 1 DM.
It is not fully understoodwhy some people develop type 2DMand
others do not. However, certain factors increase the risk, including
the following (Kim 2002).
• Weight (the more fatty tissue present, the more resistant
cells become to insulin).
• Inactivity (the less active a person is, the greater the risk.
Physical activity helps control weight, uses up glucose as energy
and makes cells more sensitive to insulin).
• Family history (risk increases if a parent or sibling has type
2 DM).
• Race (certain races - including blacks, Hispanics, American
Indians, and Asian-Americans are at higher risk, although it is
not clear why).
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• Age (risk increases as you get older, perhaps due to less
exercise, lost muscle mass, and weight gain as you age, however,
type 2 DM is also increasing dramatically among children,
adolescents, and younger adults).
• GDM (if a woman developed gestational diabetes when
pregnant, her risk of developing prediabetes and type 2 DM later
increases. If a woman gave birth to a baby weighing more than
nine pounds (four kilograms), the risk of type 2 DM also
increases).
• Polycystic ovary syndrome (a common condition
characterised by irregular menstrual periods, excess hair growth,
and obesity) increases the risk of DM).
• High blood pressure, over 140/90 millimetres of mercury
(mmHg), is linked to an increased risk of type 2 DM.
• Abnormal cholesterol and triglyceride levels (low levels of
high-density lipoprotein (HDL), or ’good’ cholesterol, result in
an increased risk of type 2 DM, as does a high level of
triglycerides).
• Gender (higher prevalence of diabetes among men, and
men develop diabetes at lower body mass index (BMI) levels
than women).
Possible complications in pregnant women with DM
and their offspring
Diabetes in pregnancy is associated with risks to the woman
and the developing fetus (Adam 2014; Ali 2011; Bartz 2012;
Billionnet 2014; Carter 2012; Feig 2014; Fraser 2014; Holman
2014; Kapoor 2007; Krane 2014; Morken 2014; Øverland 2014;
Ryu 2014; Tennant 2014; Yessoufou 2011).
• Increased risk of complications of DM, including
ketoacidosis, hypoglycaemia, retinopathy, and nephropathy.
• Increased risk of obstetric complications, including
pregnancy-induced hypertension, thromboembolism, obstructed
labour, polyhydramnios, maternal infection, caesarean section,
pre-eclampsia, and preterm labour.
• Increased risk of fetal and neonatal complications, including
miscarriage, stillbirth, congenital malformations, macrosomia,
birth injury, perinatal mortality, postnatal adaptation problems
(e.g. hypoglycaemia (reduced levels of blood sugar)), fetal
distress, respiratory distress syndrome, and jaundice.
• Long-term outcomes of offspring born to diabetic mothers
include an increased risk of obesity, impaired cognitive ability,
and type 2 diabetes.
Management of DM in pregnancy
The management of pregnant women with type 1 diabetes in-
volves the use of insulin to control blood glucose levels. During
pregnancy, a woman’s insulin requirements may increase by up to
three to four times her pre-pregnancy dose; insulin management
is tailored to the individual (McCance 2010). In type 2 diabetes,
lifestyle changes, including a healthy diet and regular exercise, are
the first line of treatment, with the use of oral hypoglycaemic
agents or insulin to lower blood glucose, if necessary. Therefore,
themanagement of diabetes in pregnancy is complex, and includes
a combination of preconception care, glycaemic control and mon-
itoring, obtaining target blood glucose levels, monitoring glycated
haemoglobin (HbA1c) levels, retinal assessment, carefully tailored
insulin treatment, ketone testing, renal assessment, monitoring fe-
tal growth and well-being, and postnatal care (Balaji 2011; Ballas
2012; NICE 2015).
Description of the intervention
Insulin is a hormone made naturally in the body by pancreatic
beta cells. This hormone controls the level of glucose in the blood.
There are different types of insulin available, which are classified
according to how quickly and for how long they work on various
parts of the body. There are also many different methods of ad-
ministering insulin, referred to as ’regimens’. This review focuses
on the efficacy and safety of different insulin types and the various
regimens of insulin delivery during pregnancy. The appropriate
insulin type and regimen for each woman will depend on a num-
ber of factors, including the type of diabetes, previous control, age,
dexterity, eyesight, and personal and cultural preferences (Greuter
2012).
Types of insulin
Insulins can be classified into various types, according to their
duration of action (Mooradian 2006; NICE 2015).
• Short-acting insulin (e.g. Humulin, Novolin): should be
injected 15 to 30 minutes before a meal, to cover the rise in
blood glucose levels that occurs after eating. This insulin has a
peak action of two to six hours, and can last for up to eight hours.
• Rapid-acting insulin analogues (e.g. Aspart, Lispro):
genetically engineered analogues of human insulin, which work
like insulin that is normally produced with a meal. Onset of
action is approximately 15 minutes, peaking at one hour, and
lasting three to four hours. They can be injected shortly before,
during, or immediately after meals.
• Long-acting insulin analogues (e.g. Detemir, Glargine):
genetically modified analogues, with an onset of action at one to
three hours; they plateau and last for 20 to 24 hours. Generally
used once- or twice-daily to produce a constant flow of insulin,
they are physiologically similar to normal endogenous basal
insulin secretion.
• Intermediate-acting (medium-acting) insulins (e.g.
isophane or neutral protamine Hagedorn (NPH)): these have an
onset of action of two to four hours, peak at six to seven hours,
and last 20 hours. Isophane insulin is ideal for twice-daily insulin
regimens, and can be mixed with soluble insulin.
• Mixed insulin (Biphasic insulin): a combination of
medium-acting and rapid-acting or short-acting insulin.
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• Mixed analogue: a combination of medium-acting insulin
and rapid-acting analogue.
Insulin regimens
In this review, the term ’insulin regimen’ refers to anoverall strategy
for insulin delivery that typically specifies:
• the frequency of insulin injections (e.g. once, twice daily);
• the type of insulin administered (e.g. intermediate-, long-
acting); and
• the timing of insulin injections (e.g. bedtime, before
breakfast).
The main insulin regimens are as follows.
Once-daily regimen
• Long- or intermediate-acting insulin administered at
bedtime in people with type 2 diabetes only.
• It may be used in addition to oral hypoglycaemic agents.
• This regimen is generally used when starting insulin in type
2 diabetes and when it is necessary for others to administer the
injections.
Twice-daily regimen
• A biphasic insulin is injected twice a day (before breakfast
and before the evening meal).
• Assumes three meals a day are consumed, and peak action
varies according to the amount of soluble insulin in the mixture.
• Optimal glycaemic control can be difficult to maintain,
resulting in hypoglycaemic episodes.
• Additional snacks are often required between meals, given
the overlap between short-acting and long-acting insulin.
Basal-bolus regimen
• Intermediate- or long-acting insulin is administered at
bedtime to cover overnight insulin requirements, and is
combined with rapid- or short-acting insulin injections to cover
mealtimes.
When intensified insulin therapy is used to provide optimal gly-
caemic control, this is the most commonly used insulin regimen,
and is also known as multiple daily injections (MDI).
Continuous subcutaneous insulin infusion, or insulin pump
therapy
• Continuous subcutaneous insulin infusion (CSII) or insulin
pump therapy is when basal insulin is given via a catheter,
supplied from a syringe reservoir worn under clothing.
• The woman can activate pre-meal boluses, and the pump
can be deactivated for up to one hour to facilitate activities, such
as swimming.
• The pump can be pre-programmed, and as a result, the
insulin absorption is more predictable than multiple daily
injections.
• CSII provides some advantages over multiple daily
injections in type 1 diabetes for children and adults who have
recurrent hypoglycaemia, delayed meals, or pre-breakfast
hyperglycaemia.
Continuous subcutaneous insulin infusion regimens have been
covered extensively in two previous Cochrane reviews, and will
not be included in the current review (Farrar 2016; Misso 2010).
Insulin dosage
Insulin dosage should be individualised to achieve and maintain
a target blood glucose level, and is determined by various factors,
including body weight, body fat, physical activity, insulin sensitiv-
ity, blood glucose levels, and target blood glucose. Insulin dosage
is usually based on body weight (insulin unit per kilogram of body
weight). One international unit of insulin (1 IU) is defined as the
’biological equivalent’ of 34.7 µg of pure crystalline insulin (Beals
2013). Daily insulin requirements may be higher during illness,
stress, pregnancy, in obese people, trauma, during concurrent use
with medications having hyperglycaemic effects, or after surgery,
andmay be lower with exercise, weight loss, calorie restricted diets,
or during concurrent use of medications having hypoglycaemic
effects. Total daily doses should not be adjusted bymore than 10%
increments. Supplemental doses may be prescribed during illness,
or to correct high preprandial blood glucose. In addition, dosage
adjustments may be required when the brand, type, or species of
insulin is changed (Teuscher 2007).
How the intervention might work
Insulin, a hormone made by beta cells of the pancreas, works on
various parts of the body when it is chemically released into the
bloodstream. This process results in the control of glucose (sugar)
levels in the blood. Normally, after you have eaten, various foods
are broken down into sugars, the main one being glucose, which
pass through the gut wall into the bloodstream. To remain healthy,
the blood glucose level should be neither too high nor too low.
For example, if the blood glucose level rises (after eating), then the
insulin level should also rise. Insulin works on the cells to make
them absorb glucose from the bloodstream, some of which is used
for energy, some of which is converted into glycogen or fat (energy
stores). When blood glucose levels fall (between meals), insulin
levels fall, and the glycogen or fat is converted back into glucose,
which is released into the cells of the bloodstream. People with
diabetes need to control the level of glucose in their blood; this is
usually tailored to their individual needs and is dependent on the
type of diabetes present. Overall, there is a lack of clear evidence
regarding the benefits and risks of the various insulin types and
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regimens, particularly the newer insulin therapies. The evidence
so far suggests that:
• rapid-acting insulin analogues may improve postprandial
hyperglycaemia and reduce hypoglycaemia (Siebenhofer 2006);
• long-acting insulin analogues may reduce nocturnal
hypoglycaemia and weight gain (Gough 2007), but some studies
found them no better than conventional NPH insulin (Home
2005; Horvath 2007);
• the newer treatments seem to be safe so far (Siebenhofer
2004);
• the rapid-acting insulin analogues (Aspart and Lispro) do
not seem to adversely affect pregnancy or the health of the fetus
or newborn baby (Negrato 2012);
• use of isophane insulin (NPH insulin) as the first choice for
long-acting insulin during pregnancy is recommended, and
insulin Detemir or Glargine in women with diabetes who have
established good blood glucose control before pregnancy (NICE
2015);
• twice-daily regimens using isophane insulin (NPH insulin)
or long-acting insulin analogues (insulin Glargine) may be more
suitable for those who require assistance, or have a dislike of
injecting (Barnett 2008);
• multiple injection regimens using unmodified or soluble
insulin or rapid-acting insulin analogues, are suitable for well-
motivated individuals with a good understanding of disease
control, or those with active or erratic lifestyles (NICE 2015).
The current review interventions may result in a better under-
standing of the following outcomes in pregnant women with pre-
existing diabetes.
Improved glycaemic control: Improvement in glycaemic control
levels (i.e. optimum HbA1c levels, fasting plasma glucose).
Reduction of hypoglycaemic or hyperglycaemic episodes: A re-
duction or absence in the number of hyperglycaemic or hypogly-
caemic episodes reported in the trials.
Safety and efficacy: Measurement of the safety and efficacy of
various insulin types and regimens.
Other: Satisfaction and quality of life reported by women; mater-
nal and infant outcomes.
Why it is important to do this review
Several Cochrane reviews have evaluated the effects of various in-
terventions for managing pre-existing diabetes in pregnancy, in-
cluding: early pregnancy screening to improve maternal and child
health; CSII versus MDI of insulin; glycaemic control; moni-
toring blood glucose during pregnancy; and oral anti-diabetic
agents for impaired glucose tolerance (Allnutt 2015; Farrar 2016;
Middleton 2012; Moy 2014; Tieu 2010a). In addition, there are
other Cochrane reviews that cover various aspects of diabetes man-
agement around conception, pregnancy, and birth (e.g. elective
delivery, exercise, antenatal breast milk expression, preconception
care, and contraceptive advice (Boulvain 2001; Ceysens 2006; East
2014; Tieu 2010b; Visser 2013)).
Our review assessed evidence related to different insulin types and
regimens, and aimed to contribute to knowledge that will ulti-
mately be used by pregnant women with pre-existing diabetes
and their clinicians, to minimise the risk of adverse birth out-
comes and complications of diabetes for mothers. This review was
timely, since currently, pregnant women with diabetes have signif-
icantly worse outcomes than women without diabetes. Achieving
improved pregnancy outcomes for women with diabetes needs to
be prioritised, particularly given that the prevalence of diabetes
among women of childbearing age is increasing. Furthermore,
while there have been advances in the different insulin types and
regimens available that have crossed into the field of obstetrics,
further research is needed to address the safety and efficacy of these
new drugs on the market to improve compliance and glycaemic
control, especially during pregnancy.
O B J E C T I V E S
To assess the effects of different insulin types and different insulin
regimens in pregnant women with pre-existing type 1 or type 2
diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials and cluster-randomised
trials, regardless of the number of trial arms that reported data that
evaluated different insulin types or regimens. We excluded quasi-
randomised controlled trials and trials using a cross-over design.
We included studies published in abstract form and contacted the
authors for further details where applicable. Conference abstracts
were superseded by full publications.
Types of participants
Women with a singleton pregnancy who had pre-existing diabetes
(type 1 or type 2) and were randomised to receive different insulin
types or regimens. Trials were excluded if women were randomised
prior to pregnancy. Women who met the diagnostic criteria for
GDM were not included. Diagnostic criteria for DM and GDM
were based on various definitions as reported by individual trial-
ists, according to local health authorities and professional organi-
sations. Women were eligible regardless of gestation, age, or parity.
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Types of interventions
We included randomised controlled trials that examined any of
the following comparisons.
Comparisons between different insulin types used within
similar insulin regimens
For example:
1. basal bolus regimen of NPH insulin given at bedtime,
combined with Aspart to cover mealtimes versus basal bolus
regimen of Glargine given at bedtime, combined with Aspart to
cover mealtimes (i.e. a comparison of the effects of different
insulin types [NPH versus Glargine] when used within a basal
bolus regimen).
Comparisons between different insulin regimens with
similar insulin types used within the regimens
For example:
1. twice-daily insulin regimen versus four times daily insulin
regimen:
• twice-daily regimen: morning dosage = one-third human
regular insulin and two-thirds human intermediate insulin;
afternoon dosage = equal parts regular and intermediate insulin;
• four-times daily regimen: first three dosages of regular
insulin 30 minutes before a meal; final dosage: bedtime,
intermediate insulin.
Comparisons between different insulin regimens with
different insulin types used within the regimens
For example:
1. a biphasic insulin injected twice a day (pre-breakfast and
pre-evening meal) versus basal bolus regimen of NPH insulin
given at bedtime, combined with Aspart to cover mealtimes.
Types of outcome measures
Primary outcomes
Infant
1. Macrosomia (birthweight greater than 4000 g, birthweight
greater than 90% for gestational age at delivery after correcting
for neonatal sex and ethnicity).
2. Perinatal death.
Maternal
1. Caesarean section (emergency or elective).
2. Pre-eclampsia.
Secondary outcomes
Infant
1. Fetal anomaly divided into major and minor.
2. Birth trauma including shoulder dystocia, nerve palsy, and
fracture.
3. Preterm birth less than 37 weeks.
4. Small-for-gestational age at delivery (weight below the 10th
percentile for gestational age at delivery).
5. Five-minute Apgar score less than seven.
6. Birthweight centile corrected for gestational age at delivery,
parity, ethnicity, maternal weight, and fetal sex (Z scores used
where available).
7. Admission and length of stay in neonatal intensive care unit.
8. Mechanical ventilation.
9. Neonatal infection.
10. Neonatal hypoglycaemia.
11. Insulin sensitivity (cord insulin, C-peptide).
12. Jaundice requiring therapy.
13. Respiratory distress syndrome.
14. Hyperbilirubinaemia.
15. Necrotising enterocolitis.
16. Intracranial haemorrhage.
17. Artifical tube feeding.
18. Composite outcome measure of neonatal morbidity
(admission and length of stay in neonatal intensive care unit,
mechanical ventilation, neonatal infection, neonatal
hypoglycaemia, insulin sensitivity (cord insulin, C-peptide),
jaundice requiring therapy, respiratory distress syndrome,
hyperbilirubinaemia, necrotising enterocolitis, intracranial
haemorrhage, artificial (tube) feeding).
19. Neonatal anthropometry (length, head circumference,
ponderal index).
20. Neonatal adiposity (fat mass, skinfold thickness, body
weight percentile).
21. Measures of growth and neurodevelopment at childhood
follow-up.
Maternal
1. Vaginal delivery (spontaneous, ventouse, forceps).
2. Postpartum haemorrhage.
3. Severe perineal trauma (third- and fourth-degree tear).
4. Measures of diabetic metabolic control (levels of HbA1c,
daily mean self-monitored blood glucose, postprandial and
fasting, continuous glucose monitoring).
5. Maternal hypoglycaemia and hyperglycaemia episodes
requiring intervention.
6. Weight gain in pregnancy.
7. Induction of labour (reasons related to diabetes).
8. Postpartum infection.
9. Breastfeeding.
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10. Retinopathy.
11. Quality of life (psychological impact of management,
assessed by psychometric testing with a reliable standardised
questionnaire).
12. Use of healthcare resources (rate of antenatal clinic visits
and admission for treatment relating to control of diabetes,
ultrasound growth scans, biophysical scans, dopplers,
cardiotocograph’s, maternal hospital days).
13. Woman’s preference and satisfaction with treatment.
14. Economic evaluation.
Outcomes not prespecified in protocol (but added to review)
Infant
1. Birthweight.
2. Infant fasting C-peptide level at three months (pmol/mL).
3. Infant C-peptide level one hour after glucose-amino acid
challenge at three months (pmol/mL).
4. Infant glucose fasting level at three months (pmol/mL).
5. Infant glucose level one hour after glucose-amino acid
challenge at three months (pmol/mL).
6. Gestational age at delivery.
Maternal
1. Ventouse delivery.
2. Maternal ketonuria.
3. Maternal compliance with treatment score (1 = best
compliance, 5 = worst compliance).
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (30 October 2016).
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter, including the detailed search strategies for CENTRAL,MED-
LINE, Embase and CINAHL, the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ’Specialized Register’ sec-
tion from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set, which has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned, and ongoing trial reports on 17 October 2016
(see: Appendix 1 for the terms we used).
Searching other resources
We examined the reference lists of included studies and any rel-
evant studies identified. Where studies could only be accessed as
abstracts, we contacted the authors for more details.
We did not apply any language or date restrictions.
Data collection and analysis
The following methods section of this review are based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors (SON, HW) independently assessed all the
potential studies identified as a result of the search strategy for
inclusion. We resolved any disagreement through discussion, or if
required, we consulted a third person (ASK).
We created a study flow diagram mapping out the number of
records identified, included, and excluded.
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors (SON, HW) independently extracted the data using the
agreed form. We resolved discrepancies through discussion, or if
required, we consulted a third person (LK). SON entered the
data into Review Manager 5 software (RevMan 5 2014) and HW
checked them for accuracy. When information regarding any of
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the above was unclear, we attempted to contact authors of the
original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors (SON, HW) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreement by discussion, or by involving a
third assessor (PK).
(1) Random sequence generation (checking for possible
selection bias)
For each included study, we described themethod used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For each included study, we described the method used to con-
ceal allocation to interventions prior to assignment, and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study, we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if theywere blinded, or if we judged that the
lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high, or unclear risk of bias for participants;
• low, high, or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study, we described the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high, or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For each included study, and for each outcome or class of out-
comes, we described the completeness of data, including attri-
tion and exclusions from the analysis. We stated whether attrition
and exclusions were reported, and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information was reported, or could
be supplied by the trial authors, we included missing data in the
analyses that we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For each included study, we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review had been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes had been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
For each included study, we described any important concerns we
had about other possible sources of bias.
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We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book of Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we assessed the likely magnitude and
direction of the bias, and whether we considered it was likely to
impact the findings. We explored the impact of the level of bias
by undertaking sensitivity analyses - see Sensitivity analysis.
Assessing the quality of the body of evidence using
the GRADE approach
We created ’Summary of findings’ tables for all comparisons made
in the review by importing data fromReviewManager 5 (RevMan
5 2014) into the GRADEpro Guideline Development Tool. The
following outcomes were included in the ’Summary of findings’
tables.
• Macrosomia.
• Perinatal death.
• Pre-eclampsia.
• Caesarean section (emergency or elective).
• Fetal anomaly.
• Birth trauma, including shoulder dystocia, nerve palsy, and
fracture.
• Composite outcome measure of neonatal morbidity
(admission and length of stay in neonatal intensive care unit,
mechanical ventilation, infection, jaundice requiring therapy,
respiratory distress syndrome, necrotising enterocolitis,
intracranial haemorrhage, artificial (tube) feeding).
The quality of the evidence for each outcome was assessed using
the GRADE approach as outlined in the GRADE Handbook.
We downgraded the evidence from high quality by one level for
serious (or by two levels for very serious) limitations, depending
on our assessments of the risk of bias, indirectness of evidence,
serious inconsistency, imprecision of effect estimates, or potential
publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratios
(RR) with 95% confidence intervals (CI).
Continuous data
For continuous data, we used the mean difference (MD) if out-
comes were measured in the same way between trials. We had
planned to use the standardised mean difference (SMD) to com-
bine trials that measured the same outcome, but used different
methods, but there were no such trials in this review.
Unit of analysis issues
Cluster-randomised trials
We did not include any cluster-randomised trials in this review. In
future updates, if we identify eligible cluster-randomised trials, we
will include their data in the analyses along with individually-ran-
domised trials. We will adjust their sample sizes using the methods
described in the Cochrane Handbook of Systematic Reviews of Inter-
ventions (Sections 16.3.4 or 16.3.6), using an estimate of the intra
cluster correlation co-efficient (ICC) derived from the trial (if pos-
sible), from a similar trial, or from a study of a similar population.
If we use ICCs from other sources, we will report this and con-
duct sensitivity analyses to investigate the effect of variation in the
ICC. If we identify both cluster-randomised trials and individu-
ally-randomised trials, we will synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs, and we
consider it unlikely that there will be an interaction between the
effect of the intervention and the choice of randomisation unit.
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Multi-armed trials
We included multi-armed trials and recorded all outcome data
in the review as two-arm comparisons. We included the data for
different arms in independent two-arm comparisons in separate
meta-analyses where possible. If we were unable to include the
data in separate comparisons, we combined them to create a single
pair-wise comparison (Higgins 2011). If the control group was
shared by two or more study arms, we divided the control group
between relevant subgroup categories to avoid double counting
the participants. For dichotomous data, we divided the events
and the total population, while for continuous data, we assumed
the same mean and standard deviation (SD) divided by the total
population.
Cross-over trials
Cross-over trials were not eligible for inclusion in this review.
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Dealing with missing data
Wenoted levels of attrition in the included studies. If more eligible
studies are included In future updates, we will explore the impact
of including studies with high levels of missing data in the overall
assessment of the treatment effect by using sensitivity analyses.
Analyses were carried out for all outcomes, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partic-
ipants were analysed in the group to which they were allocated,
regardless of whether they received the allocated intervention. The
denominator for each outcome in each trial was the number ran-
domised minus any participants whose outcomes were known to
be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I², and Chi² statistics. We regarded heterogeneity as
substantial if an I² was greater than 30%, and either a Tau² was
greater than zero, or the P was less than 0.10 in the Chi² test for
heterogeneity.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will first visually assess funnel plot
asymmetry. If asymmetry is suggested by a visual assessment, we
will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager 5
software (RevMan 5 2014). We did not combine the results from
different trials as each trial looked at a different comparison. If
we had pooled the data in a meta-analysis, we would have used
a fixed-effect model for combining data where it was reasonable
to assume that studies were estimating the same underlying treat-
ment effect, i.e. where trials were examining the same interven-
tion, and the trials’ populations and methods were judged to be
sufficiently similar. If there was sufficient clinical heterogeneity
to expect that the underlying treatment effects differed between
trials, or if substantial statistical heterogeneity was detected, we
had planned to use a random-effects model to produce an overall
summary, if an average treatment effect across trials was consid-
ered clinically meaningful. The random-effects summary would
have been treated as the average of the range of possible treatment
effects, and we had planned to discuss the clinical implications of
treatment effects differing between trials. If the average treatment
effect was not clinically meaningful, we had planned not to com-
bine trials.
If we hadused random-effects analyses, the resultswould have been
presented as the average treatment effect with 95% confidence
intervals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
It is very unlikely that an investigation of heterogeneity will pro-
duce useful findings unless there is a substantial number of studies
(at least 10 studies for each characteristic in the meta-analysis),
according to section 9.6.5.1 in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Had we identified
substantial heterogeneity, we had planned to investigate it using
subgroup analyses and sensitivity analyses, to consider whether an
overall summary was meaningful, and if it was, to use the random-
effects model to produce it.
We had planned to carry out the following subgroup analyses on
the review’s primary outcomes, but there were insufficient data to
do so:
1. by type of diabetes (type 1 versus type 2);
2. gestational age when women were recruited to the trial (less
than 12 weeks versus more than 12 weeks);
3. maternal age (younger than 35 years versus older than 35
years);
4. body mass index (at or before trial entry), overweight (more
than 25 kg/m²) versus normal weight (25 kg/m² or less), and
obese (more than 30 kg/m²) versus normal weight (25 kg/m² or
less);
5. by unit of randomisation (randomised by individual
participant versus randomised by cluster).
In future updates, we plan to assess subgroup differences by in-
teraction tests available in RevMan 5 (RevMan 5 2014). We will
report the results of subgroup analyses quoting the Chi² statistic
and P value, and the interaction test, I² value.
Sensitivity analysis
We had planned to carry out the following sensitivity analyses for
the reviews primary outcomes, but there were insufficient data to
do so. In future updates, we will compare trials judged as having
a low risk of bias for allocation concealment with trials judged
to have unclear or high risk of bias, in order to assess any sub-
stantive differences in the overall result. We will also carry out a
sensitivity analysis to explore the fixed-effect model or random-
effects model analyses for primary outcomes with statistical het-
erogeneity. If ICCs from other sources are used, we will conduct
sensitivity analyses to investigate the effect of variation in the ICC.
As noted in Section 9.7 of the Cochrane Handbook for Systematic
Reviews of Interventions, “many issues suitable for sensitivity anal-
ysis are only identified during the review process when the indi-
vidual peculiarities of the studies under investigation are identi-
fied” (Higgins 2011). If it is deemed appropriate in updates of the
review to conduct further sensitivity analyses (in addition to the
pre-specified analyses outlined above), we will explain the reasons
for conducting these additional analyses in our review, and the
analyses will be clearly labelled as ’non-prespecified analyses’.
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R E S U L T S
Description of studies
See Characteristics of included studies.
Results of the search
From the search of the Cochrane Pregnancy and Childbirth
Group’s Trials Register (October 2016), we retrieved 34 full-
text reports. We also found two additional reports by searching
ClinicalTrials.gov and theWHOInternational Clinical Trials Reg-
istry Platform (ICTRP; 17 October 2016). When we assessed
these reports for eligibility, by applying the inclusion and exclu-
sion criteria, we were left with five trials eligible to be included in
the review (see Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Design
Four trials were open-label, multi-centre, two-armed RCTs (
Jovanovic-Peterson 1992; Mathiesen 2007; Mathiesen 2012;
Persson 2002). One trial was a single centre, four-armed RCT
(Schuster 1998).
Sample sizes
There were 43 women included in the trial by Jovanovic-Peterson
1992 (N = 20 intervention arm, N = 23 control arm), 33 women
in the trial by Persson 2002 (N = 16 intervention arm, N = 17
control arm), 223 women in the trial byMathiesen 2007 (N = 113
intervention arm, N = 110 control arm), 162 women in the trial
byMathiesen 2012 (N = 79 intervention arm,N= 83 control arm)
and 93 women in the trial by Schuster 1998 (N = 24 intervention
arm1, N = 22 intervention arm2, N = 23 intervention arm3, N =
24 control arm).
Setting
Two trials were conducted in the USA (Jovanovic-Peterson 1992;
Schuster 1998), one trial was conducted in Sweden (Persson 2002),
and the remaining two trials were conducted in 63 sites in 18
countries, and 79 sites in 17 countries respectively, mainly within
Europe (Mathiesen 2007, Mathiesen 2012).
Participants
Participants included pregnant women with type 1 DM (
Jovanovic-Peterson 1992; Mathiesen 2007; Mathiesen 2012;
Persson 2002; Schuster 1998), or type 2 DM (Jovanovic-Peterson
1992), recruited from hospitals in each specific region.
Interventions and comparisons
Different insulin types within similar insulin regimens
Four trials compared different insulin types within similar insulin
regimens (Jovanovic-Peterson 1992; Mathiesen 2007; Mathiesen
2012; Persson 2002).
Persson 2002 compared the rapid-acting insulin analogue Lispro
(Humalog®) plus the intermediate-acting insulin NPH (within
a MDI basal bolus regimen) to regular short-acting insulin (Hu-
mulin Regular®/Actrapid®) plus the intermediate-acting insulin
NPH.
Jovanovic-Peterson 1992 compared short-acting human insulin
(recombinant deoxyribonucleic acid - Humulin®) to animal in-
sulin.
Mathiesen 2007 compared rapid-acting insulin Aspart (plus the
intermediate-acting insulin NPH) to human insulin (plus the in-
termediate-acting insulin NPH).
Mathiesen 2012 compared long-acting insulin Detemir (plus
rapid-acting insulin Aspart) to intermediate-acting NPH insulin
(plus rapid-acting insulin Aspart).
Different insulin regimens with similar insulin types used
within the regimens
One trial compared three different interventions; for the purpose
of this review, we combined the data as follows (Schuster 1998).
1. We compared pre-mixed (70 NPH/30 REG) insulin to self-
mixed split dose insulin.
2. We compared insulin injected with a Novolin pen to
insulin injected with a conventional needle or syringe.
Outcomes
Primary outcomes
Infant
1. Macrosomia was reported in two trials (Jovanovic-Peterson
1992; Schuster 1998).
2. Perinatal death was reported in one trial (Persson 2002).
Maternal
1. Caesarean section (emergency or elective) was reported in
two trials (Persson 2002; Schuster 1998).
2. Pre-eclampsia was reported in one trial (Persson 2002).
Secondary outcomes
Infant
1. Fetal anomaly divided into major and minor was reported
in two trials (Mathiesen 2012; Persson 2002).
2. Birth trauma, including shoulder dystocia, nerve palsy, and
fracture was reported in one trial (Persson 2002).
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3. Preterm birth, at less than 37 weeks, was reported in one
trial (Jovanovic-Peterson 1992).
4. Small-for-gestational age at delivery (weight below the 10th
percentile for gestational age at delivery) was reported in one trial
(Jovanovic-Peterson 1992).
5. Birthweight centile, corrected for gestational age at delivery,
parity, ethnicity, maternal weight, and fetal sex (Z scores used
where available) was reported in one trial (Jovanovic-Peterson
1992).
6. Neonatal anthropometry (length, head circumference,
ponderal index): Infant length and head circumference were
reported in one trial (Jovanovic-Peterson 1992).
7. Neonatal adiposity (fat mass, skinfold thickness, body
weight percentile): skinfold thickness and body weight percentile
were reported in one trial (Jovanovic-Peterson 1992).
Maternal
1. Vaginal delivery (spontaneous, ventouse, forceps) was
reported in one trial (Persson 2002).
2. Measures of diabetic metabolic control (levels of HbA1c,
daily mean self-monitored blood glucose, post-prandial and
fasting, continuous glucose monitoring): levels of HbA1c at the
third trimester visit were reported in one trial (Mathiesen 2007);
blood glucose at week 14 (after lunch), was reported in one trial
(Persson 2002); blood glucose at weeks 21, 28, and 34 combined
(after lunch), was reported in one trial (Persson 2002);
postprandial increase of blood glucose before week 14 (after
lunch) was reported in one trial (Persson 2002); postprandial
increase of blood glucose during weeks 21, 28 and 34 combined
(after lunch) was reported in one trial (Persson 2002);
antepartum capillary glucose measure (mg/dL), two hours post
prandial (after lunch) was reported in one trial (Schuster 1998);
insulin requirement during pregnancy (U/kg/24 hour) was
reported in one trial (Jovanovic-Peterson 1992).
3. Maternal hypoglycaemia and hyperglycaemia episodes
requiring intervention were reported in two trials (Mathiesen
2007; Persson 2002).
4. Postpartum infection was reported in one trial (Schuster
1998).
5. Retinopathy was reported in one trial (Persson 2002).
6. Use of healthcare resources (rate of antenatal clinic visits
and admission for treatment relating to control of diabetes,
ultrasound growth scans, biophysical scans, dopplers,
cardiotocograph’s, maternal hospital days): maternal hospital
days were reported in one trial (Schuster 1998).
Outcomes not prespecified in protocol
Infant
1. Birthweight was reported in two trials (Jovanovic-Peterson
1992; Schuster 1998).
2. Infant fasting C-peptide level at three months (pmol/mL)
was reported in one trial (Jovanovic-Peterson 1992).
3. Infant C-peptide level 1 hour after glucose-amino acid
challenge at three months (pmol/mL) was reported in one trial
(Jovanovic-Peterson 1992).
4. Infant glucose fasting level at three months (pmol/mL) was
reported in one trial (Jovanovic-Peterson 1992).
5. Infant glucose level 1 hour after glucose-amino acid
challenge at three months (pmol/mL) was reported in one trial
(Jovanovic-Peterson 1992).
6. Gestational age at delivery was reported in one trial
(Jovanovic-Peterson 1992).
Maternal
1. Ventouse delivery was reported in one trial (Persson 2002).
2. Maternal compliance with treatment score (1 = best
compliance, 5 = worst compliance) was reported in one trial
(Schuster 1998).
3. Maternal ketonuria was reported in one trial
(Jovanovic-Peterson 1992).
Prespecified outcomes not reported
Infant
1. Five-minute Apgar score less than seven.
2. Admission and length of stay in neonatal intensive care unit.
3. Mechanical ventilation.
4. Neonatal infection.
5. Neonatal hypoglycaemia.
6. Insulin sensitivity (cord insulin, C-peptide).
7. Jaundice requiring therapy.
8. Respiratory distress syndrome.
9. Hyperbilirubinaemia.
10. Necrotising enterocolitis.
11. Intracranial haemorrhage.
12. Artificial (tube) feeding.
13. Composite outcome measure of neonatal morbidity
(admission and length of stay in neonatal intensive care unit,
mechanical ventilation, neonatal infection, neonatal
hypoglycaemia, insulin sensitivity (cord insulin, C-peptide),
jaundice requiring therapy, respiratory distress syndrome,
hyperbilirubinaemia, necrotising enterocolitis, intracranial
haemorrhage, artificial (tube) feeding).
14. Measures of growth and neurodevelopment at childhood
follow-up.
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Maternal
1. Postpartum haemorrhage.
2. Severe perineal trauma (third- and fourth-degree tear).
3. Weight gain in pregnancy.
4. Induction of labour (reasons related to diabetes).
5. Breastfeeding.
6. Quality of life (psychological impact of management,
assessed by psychometric testing with a reliable standardised
questionnaire).
7. Woman’s preference and satisfaction with treatment.
8. Economic evaluation.
Excluded studies
We excluded Carr 2004 and Murphy 2011 because they used a
cross-over study design. We excluded Herrera 2015b; Kipikasa
2008; Mohd 2012; Nachum 1999; and Nor 2007 because they
included women with gestational diabetes. Porta 2011; Reller
1985; and Secher 2012 did not include suitable interventions. See
Characteristics of excluded studies.
Risk of bias in included studies
Overall, the five trials had a high risk of bias, due to lack of allo-
cation concealment, lack of blinding, incomplete outcome data,
and selective reporting of outcomes (Figure 2, Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Two trials described themethodof sequence generationused (com-
puter-generated randomisation (Persson 2002; Schuster 1998)).
Three trials had an unclear risk of bias, as the method of random
sequence generation was not described (Jovanovic-Peterson 1992;
Mathiesen 2007; Mathiesen 2012).
Allocation concealment
Two trials provided sufficient details on the method of allocation
concealment (sealed opaque envelopes (Mathiesen 2012; Schuster
1998)). One trial had a high risk of bias for allocation concealment
(open-label (Jovanovic-Peterson 1992)). Two trials had an unclear
risk of allocation concealment, which was not reported in the trials
(Mathiesen 2007; Mathiesen 2012).
Blinding
Performance bias
It was difficult to blind the women and staff to the interventions
of insulin types or insulin regimens. All five trials had a high risk of
performance bias, as the participants were aware of the treatment
they were receiving. For personnel, one trial reported blinding
personnel to the intervention, so this was deemed to have a low
risk of bias (Schuster 1998), whilst the other four trials (Jovanovic-
Peterson 1992; Mathiesen 2007; Mathiesen 2012; Persson 2002)
did not blind personnel, and these were deemed to have a high
risk of bias.
Detection bias
Two trials had a high risk of detection bias (open-label (Mathiesen
2007; Persson 2002)), Three trials had an unclear risk of detection
bias, which was not described in two of them (Jovanovic-Peterson
1992; Schuster 1998), and one trial reported blinding of out-
come assessment for only one outcome (congenital malformations
(Mathiesen 2012)).
Incomplete outcome data
Only one trial adequately described losses to follow-up, and
women were equally distributed between the four groups in
this study (Schuster 1998). Details regarding attrition bias were
not reported in the other four trials (Jovanovic-Peterson 1992;
Mathiesen 2007; Mathiesen 2012; Persson 2002).
Selective reporting
Two trials had an unclear risk of bias, as no protocol for either trial
was available, and therefore, it was not clear whether all prespec-
ified outcomes were reported (Jovanovic-Peterson 1992; Schuster
1998). Three trials were deemed to have high risk of reporting bias
(Mathiesen 2007; Mathiesen 2012; Persson 2002). In the trial by
Persson 2002, some outcomeswere described as showing no differ-
ences, but these figures are not given. For two trials, we included a
subgroup of women who were pregnant at randomisation, and for
these women, very few outcomes were reported (Mathiesen 2007;
Mathiesen 2012). Contact with the authors to gain information
on this subgroup proved unsuccessful.
Other potential sources of bias
Three trials had unclear risk of bias (Mathiesen 2007; Mathiesen
2012; Persson 2002). One trial reported that there were no sig-
nificant differences between the two treatment groups with regard
to baseline characteristics, however, significantly more women in
the Lispro group had aneurysms (Persson 2002), and two trials
were funded by the pharmaceutical company Novo Nordisk©
(Mathiesen 2007; Mathiesen 2012). Two trials had a low risk of
bias as it was reported that there was no difference in baseline
characteristics between the two groups, which was clear from the
tables (Jovanovic-Peterson 1992; Schuster 1998).
Effects of interventions
See: Summary of findings for the main comparison Lispro
versus regular insulin (Different insulin typeswithin similar insulin
regimens); Summary of findings 2Human insulin versus animal
insulin (Different insulin types within similar insulin regimens);
Summary of findings 3 Pre-mixed insulin (70 NPH/30 REG)
versus self-mixed split dose insulin (Different insulin regimens
with similar insulin types used within the regimen); Summary
of findings 4 Insulin injected with a Novolin pen versus insulin
injected with a needle or syringe (Different insulin regimens
with similar insulin types used within the regimen); Summary
of findings 5 Insulin Aspart (+ NPH) compared to human
insulin (+ NPH insulin) for pregnant women with pre-existing
diabetes (Different insulin types within similar insulin regimens);
Summary of findings 6 Insulin Detemir + prandial insulin Aspart
versus NPH insulin + prandial insulin Aspart (Different insulin
types within similar insulin regimens)
See: Summary of findings for the main comparison, Lispro ver-
sus regular insulin (Different insulin types within similar insulin
regimens); Summary of findings 2, Human insulin (recombinant
deoxyribonucleic acid - Humulin) versus animal insulin (Differ-
ent insulin types within similar insulin regimens); Summary of
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findings 3, Pre-mixed insulin (70NPH/30REG) versus self-mixed
split dose insulin (Different insulin regimens with similar insulin
types used within the regimen); Summary of findings 4, Insulin
injected with a Novolin pen versus insulin injected with a nee-
dle/syringe (Different insulin regimens with similar insulin types
used within the regimen); Summary of findings 5, Insulin Aspart
plus NPH insulin versus Human insulin plus NPH insulin (Dif-
ferent insulin types within similar insulin regimens); Summary of
findings 6, Insulin Detemir plus prandial insulin Aspart versus
NPH insulin plus prandial insulin Aspart (Different insulin types
within similar insulin regimens).
1. Lispro versus regular insulin (Different insulin types
within similar insulin regimens)
See Summary of findings for the main comparison. We included
one trial in this comparison, involving a total of 33 women
(Persson 2002). The evidence was downgraded to very low-quality
for all the outcomes supported by this trial for the following rea-
sons: study limitations (there was a high or unclear risk of bias for
allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selec-
tive outcome reporting, and other biases), and sparse data (one
small study, few events for the outcomes, very wide confidence
intervals often crossing the line of no effect).
Primary outcomes
Infant
There were no perinatal deaths in the Lispro or regular insulin
group (Analysis 1.1).
Maternal
There was very low-quality evidence from one study (33 women)
of no clear difference between insulin Lispro and regular insulin
in the primary maternal outcomes of caesarean section (risk ra-
tio (RR) 0.59, 95% confidence interval (CI) 0.25 to 1.39; 33
women; Analysis 1.2), and pregnancy-induced hypertension or
pre-eclampsia (RR 0.68, 95% CI 0.35 to 1.30; Analysis 1.3).
Secondary outcomes
Infant
There was very low-quality evidence from one study (33 infants)
of no clear difference between insulin Lispro and regular insulin in
the secondary infant outcomes of fetal anomaly (RR 0.35, 95%CI
0.02 to 8.08; Analysis 1.4). There were no cases of birth trauma,
including shoulder dystocia, nerve palsy, and fracture in either
group (Analysis 1.5).
Maternal
There was very low-quality evidence from one study (33 women)
of no clear differences between insulin Lispro and regular insulin
in the secondary maternal outcomes of vaginal delivery (sponta-
neous, ventouse, forceps (RR 1.46, 95% CI 0.80 to 2.67; Analysis
1.6), and measures of diabetic metabolic control: blood glucose at
week 14 after lunch (mean difference (MD) -1.09 mmol/L, 95%
CI -3.60 to 1.42; Analysis 1.7); blood glucose after lunch at weeks
21, 28, and 34 combined (MD -0.04 mmol/L, 95% CI -2.10 to
2.02; Analysis 1.8); increase of blood glucose after lunch before
week 14 (MD 1.00 mmol/L, 95% CI -1.52 to 3.52; Analysis 1.9);
increase of blood glucose after lunch during weeks 21, 28, and 34
combined (MD 0.10 mmol/L, 95% CI -2.12 to 2.32; Analysis
1.10); maternal hypoglycaemia and hyperglycaemia episodes re-
quiring intervention (RR 0.21, 95% CI 0.01 to 4.10; Analysis
1.11); and retinopathy (RR 1.06, 95% CI 0.17 to 6.67; Analysis
1.12). Caution is advised in interpreting the data where there are
wide confidence intervals, small sample size, and low event rates
in this comparison.
Outcomes not prespecified in protocol
Maternal
There was very low-quality evidence from one study (33 women)
of no clear difference between insulin Lispro and regular insulin
for ventouse delivery (RR 3.19, 95% CI 0.37 to 27.58; Analysis
1.13).
Outcomes not reported
Infant
Macrosomia, preterm birth at less than 37 weeks; small-for-ges-
tational age at delivery; five-minute Apgar score less than seven;
birthweight centile corrected for gestational age at delivery, parity,
ethnicity, maternal weight, and fetal sex; admission and length of
stay in neonatal intensive care unit; mechanical ventilation; neona-
tal infection; jaundice requiring therapy; respiratory distress syn-
drome; necrotising enterocolitis; intracranial haemorrhage; artifi-
cial (tube) feeding; and the composite outcome measure of neona-
tal morbidity (admission and length of stay in neonatal inten-
sive care unit; mechanical ventilation; neonatal infection; jaun-
dice requiring therapy; respiratory distress syndrome; necrotising
enterocolitis; intracranial haemorrhage; artificial (tube) feeding);
neonatal anthropometry (length, head circumference, ponderal
index); neonatal adiposity (fat mass, skinfold thickness); measures
22Different insulin types and regimens for pregnant women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of growth and neurodevelopment at childhood follow-up; birth-
weight; infant fasting C-peptide level at three months; infant C-
peptide level one hour after glucose-amino acid challenge at three
months; infant glucose fasting level at threemonths; infant glucose
level one hour after glucose-amino acid challenge at three months;
gestational age at delivery.
Maternal
Postpartum haemorrhage; severe perineal trauma (third- and
fourth-degree tear); weight gain in pregnancy; induction of labour
(reasons related to diabetes); postpartum infection; breastfeed-
ing; quality of life (psychological impact of management, assessed
by psychometric testing with a reliable standardised question-
naire); use of healthcare resources (rate of antenatal clinic visits
and admission for treatment relating to control of diabetes, ul-
trasound growth scans, biophysical scans, dopplers, cardiotoco-
graph’s); women’s preference and satisfaction with treatment; an
economic evaluation; maternal ketonuria; maternal compliance
with treatment score (1 = best compliance, 5 = worst).
2. Human insulin (recombinant deoxyribonucleic acid
- Humulin) versus animal insulin (Different insulin
types within similar insulin regimens)
See Summary of findings 2. We included one trial in this com-
parison (Jovanovic-Peterson 1992) involving a total of 42 women.
The evidence supporting outcomes was downgraded to very low
for the following reasons: study limitations (high or unclear risk
of bias for allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete outcome
data, selective outcome reporting, and other biases), and sparse
data (one small study, few events for the outcomes, very wide con-
fidence intervals often crossing the line of no effect).
Primary outcomes
Infant
There was very low-quality evidence from one study (42 infants)
of no clear difference between human insulin and animal insulin
in the primary infant outcome of macrosomia (RR 0.22, 95% CI
0.01 to 4.30; Analysis 2.8).
Maternal
None reported.
Secondary outcomes
Infant
There was very low-quality evidence from one study (42 infants)
of no clear differences between human insulin and animal insulin
for: preterm birth less than 37 weeks (RR 7.67, 95% CI 0.42 to
139.83, Analysis 2.2), birthweight centile (MD -6.70%, 95% CI
-23.64% to 10.24%; Analysis 2.3), infant length (MD -3.30 cm,
95% CI -6.74 to 0.14; Analysis 2.4), skinfold thickness (MD -
4.10 mm, 95% CI -13.28 to 5.08; Analysis 2.5), or body weight
percentile (MD -6.70%, 95% CI -23.64 to 10.24; Analysis 2.6).
The infants of women who were in the human insulin group
had a smaller mean head circumference than those in the animal
insulin group (MD -5.10 cm, 95% CI -9.52 to -0.68; Analysis
2.7). There were no cases of babies who were small-for-gestational
age at delivery (Analysis 2.1).
Maternal
There was very low-quality evidence from one study (42 women)
that for the measure of diabetic metabolic control, women in the
human insulin grouphad a lowermean insulin requirement during
pregnancy (MD -0.33 U/kg/24 hour, 95% CI -0.45 to -0.21;
Analysis 2.9) compared to women in the animal insulin group.
Outcomes not prespecified in protocol
Infant
There was very low-quality evidence from one study (42 infants)
that infants in the human group had a lower mean birthweight
(MD -591.00 g, 95% CI -1066.27 to -115.73; Analysis 2.10), a
very slightly lower infant fasting C-peptide level at three months
(MD -0.07 pmol/mL, 95% CI -0.13 to -0.01; Analysis 2.11), and
a lower infant C-peptide level one hour after glucose amino acid
challenge at three months (MD -0.11 pmol/mL, 95% CI -0.19
to -0.03; Analysis 2.12). No clear difference was found for infant
glucose fasting level at three months (MD -0.20 pmol/mL, 95%
CI -0.62 to 0.22; Analysis 2.13); infant glucose level one hour after
glucose amino acid challenge at three months (MD 0.50 pmol/
mL, 95% CI -0.04 to 1.04; Analysis 2.14), or gestational age at
delivery (MD 0.50 weeks, 95% CI -3.70 to 4.70; Analysis 2.15).
Maternal
There was very low-quality evidence from one study (42 women)
that the human insulin group had an unclear lower risk ofmaternal
ketonuria (RR 0.37, 95% CI 0.08 to 1.61; Analysis 2.16).
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Outcomes not reported
Infant
Perinatal death; fetal anomaly; birth trauma including shoulder
dystocia, nerve palsy and fracture; five-minute Apgar score less
than seven; birthweight centile corrected for gestational age at de-
livery, parity, ethnicity, maternal weight and fetal sex; admission
and length of stay in neonatal intensive care unit; mechanical ven-
tilation; neonatal infection; jaundice requiring therapy; respiratory
distress syndrome; necrotising enterocolitis; intracranial haemor-
rhage; artificial (tube) feeding; a composite outcome measure of
neonatal morbidity (admission and length of stay in neonatal in-
tensive care unit, mechanical ventilation, neonatal infection, jaun-
dice requiring therapy, respiratory distress syndrome, necrotising
enterocolitis, intracranial haemorrhage, artificial (tube) feeding)
and measures of growth and neurodevelopment at childhood fol-
low-up.
Maternal
Caesarean section; pre-eclampsia; vaginal delivery (spontaneous,
ventouse, forceps); postpartum haemorrhage; severe perineal
trauma (third- and fourth-degree tear); maternal hypoglycaemia
and hyperglycaemia episodes requiring intervention; weight gain
in pregnancy; induction of labour (reasons related to diabetes);
postpartum infection; breastfeeding; retinopathy; quality of life;
use of healthcare resources; women’s preference and satisfaction
with treatment; an economic evaluation; ventouse delivery; and
maternal compliance with treatment score (1 = best, 5 = worst
compliance).
3. Pre-mixed insulin (70 NPH/30 REG) versus self-
mixed split dose insulin (Different insulin regimens
with similar insulin types used within the regimen)
See Summary of findings 3. We included one trial in this compar-
ison (Schuster 1998) involving a total of 93 women. The evidence
supporting the outcomes was downgraded to very low for the fol-
lowing reasons: study limitations (high or unclear risk of bias for
allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selec-
tive outcome reporting, and other biases), and sparse data (one
small study, few events for the outcomes, very wide confidence
intervals often crossing the line of no effect).
Primary outcomes
Infant
There was very low-quality evidence from one study (93 infants)
of no clear difference between pre-mixed insulin and self-mixed
insulin formacrosomia (RR 0.49, 95% CI 0.09 to 2.54; Analysis
3.1)
Maternal
There was very low-quality evidence from one study (93 women)
of no clear difference between pre-mixed insulin and self-mixed
insulin for caesarean section (RR 0.57, 95% CI 0.25 to 1.32;
Analysis 3.2)
Secondary outcomes
Infant
None reported.
Maternal
There was very low-quality evidence from one study (93 women)
that the pre-mixed insulin group had significantly lower measures
of diabetic metabolic control, measured by antepartum capillary
glucose taken two hours after lunch (MD -11.25 mg/dL, 95% CI
-12.55 to -9.95; 10,218 tests performed on 93 women; Analysis
3.3) compared to the self-mixed insulin group. There was no clear
difference between the pre-mixed insulin and self-mixed insulin
groups for postpartum infection (endometritis; RR 0.52, 95%
CI 0.26 to 1.04; Analysis 3.4); and use of healthcare resources
(maternal hospital days;MD-0.50, 95%CI -1.40 to 0.41; Analysis
3.5)
Outcomes not prespecified in protocol
Infant
There was very low-quality evidence from one study (93 infants)
that there was no clear difference between the pre-mixed and self-
mixed insulin groups for birthweight (MD -116.56 g, 95% CI -
391.81 to 158.69; Analysis 3.6).
Maternal
There was very low-quality evidence from one study (93 women)
that there was no clear difference between the two groups in terms
of the women’s compliance score (ranges from 1 to 5, 1 = best, 5
= worst; MD 0.00, 95% CI -0.87 to 0.87; Analysis 3.7).
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Outcomes not reported
Infant
Perinatal death; fetal anomaly; birth trauma including shoulder
dystocia, nerve palsy and fracture; preterm birth at less than 37
weeks; small-for-gestational age at delivery; five-minute Apgar
score less than seven; birthweight centile corrected for gestational
age at delivery, parity, ethnicity, maternal weight and fetal sex; ad-
mission and length of stay in neonatal intensive care unit; mechan-
ical ventilation; neonatal infection; neonatal hypoglycaemia; in-
sulin sensitivity (cord insulin, C-peptide); jaundice requiring ther-
apy; respiratory distress syndrome; hyperbilirubinaemia; necrotis-
ing enterocolitis; intracranial haemorrhage; artificial (tube) feed-
ing; a composite outcome of neonatal morbidity (admission and
length of stay in neonatal intensive care unit, mechanical ventila-
tion, neonatal infection, neonatal hypoglycaemia, insulin sensitiv-
ity (cord insulin, C-peptide), jaundice requiring therapy, respira-
tory distress syndrome, hyperbilirubinaemia, necrotising entero-
colitis, intracranial haemorrhage, artificial (tube) feeding); neona-
tal anthropometry (length, head circumference, ponderal index);
neonatal adiposity (fat mass, skinfold thickness) and measures of
growth andneurodevelopment at childhood follow-up; infant fast-
ing C-peptide level at three months; infant C-peptide level one
hour after glucose-amino acid challenge at three months; infant
glucose fasting level at three months; infant glucose level one hour
after glucose-amino acid challenge at threemonths; gestational age
at delivery.
Maternal
Pre-eclampsia; vaginal delivery (spontaneous, ventouse, forceps);
postpartum haemorrhage; severe perineal trauma (third- and
fourth-degree tear), maternal hypoglycaemia and hyperglycaemic
episodes requiring intervention; weight gain in pregnancy; induc-
tionof labour (reasons related todiabetes); breastfeeding; retinopa-
thy; quality of life (psychological impact of management assessed
by psychometric testing using a reliable standardised question-
naire); women’s preference and satisfactionwith treatment; an eco-
nomic evaluation; ventouse delivery; maternal ketonuria.
4. Insulin injected with a Novolin pen versus insulin
injected with a needle/syringe (Different insulin
regimens with similar insulin types used within the
regimen)
See Summary of findings 4. We included one trial in this compar-
ison (Schuster 1998) involving a total of 93 women. The evidence
for the outcomes was downgraded to very low for the following
reasons: study limitations (high or unclear risk of bias for alloca-
tion concealment, blinding of participants and personnel, blind-
ing of outcome assessment, incomplete outcome data, selective
outcome reporting, and other biases) and sparse data (one small
study, few events for the outcomes, very wide confidence intervals
often crossing the line of no effect).
Primary outcomes
Infant
There was very low-quality evidence from one study (93 infants)
of no clear difference between injecting with the Novolin pen and
a conventional needle or syringe for macrosomia (RR 0.21, 95%
CI 0.03 to 1.76; Analysis 4.1).
Maternal
There was very low-quality evidence from one study (93 women)
of a difference between the two groups for caesarean section (RR
0.38, 95% CI 0.15 to 0.97; Analysis 4.2).
Secondary outcomes
Infant
None reported.
Maternal
There was very low-quality evidence from one study (93 women)
that the Novolin pen group had a lower mean measure of dia-
betic metabolic control, measured by antepartum capillary glu-
cose, taken two hours after lunch (MD -7.23 mg/dL), 95% CI
-8.51 to -5.95; 10,218 tests performed on 93 women; Analysis
4.3) compared to the conventional syringe or needle group. There
was no clear difference between injecting with the Novolin pen
and a conventional needle or syringe for postpartum infection (en-
dometritis; RR 0.56, 95% CI 0.28 to 1.14; Analysis 4.4) and use
of healthcare resources (maternal hospital days; MD -0.56, 95%
CI -1.45 to 0.33; Analysis 4.5).
Outcomes not prespecified in protocol
Infant
There was very low-quality evidence from one study (93 infants)
of no clear difference between injecting with the Novolin pen and
a conventional needle or syringe for birthweight (MD -162.36 g,
95% CI -438.25 to 113.53; Analysis 4.6).
Maternal
There was very low-quality evidence from one study (93 women)
of no clear difference between the two groups in the women’s
compliance score (ranges from 1 to 5, 1 = best compliance, 5 =
worst compliance; MD -0.21, 95% CI -0.83 to 0.41; Analysis
4.7).
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Outcomes not reported
Infant
Perinatal death; fetal anomaly; birth trauma including shoulder
dystocia, nerve palsy and fracture; preterm birth at less than 37
weeks; small-for-gestational age at delivery; five-minute Apgar
score less than seven; birthweight centile corrected for gestational
age at delivery, parity, ethnicity, maternal weight and fetal sex; ad-
mission and length of stay in neonatal intensive care unit; mechan-
ical ventilation; neonatal infection; neonatal hypoglycaemia; in-
sulin sensitivity (cord insulin, C-peptide); jaundice requiring ther-
apy; respiratory distress syndrome; hyperbilirubinaemia; necrotis-
ing enterocolitis; intracranial haemorrhage; artificial (tube) feed-
ing; a composite outcome of neonatal morbidity (admission and
length of stay in neonatal intensive care unit, mechanical ventila-
tion, neonatal infection, neonatal hypoglycaemia, insulin sensitiv-
ity (cord insulin, C-peptide), jaundice requiring therapy, respira-
tory distress syndrome, hyperbilirubinaemia, necrotising entero-
colitis, intracranial haemorrhage, artificial (tube) feeding); neona-
tal anthropometry (length, head circumference, ponderal index);
neonatal adiposity (fat mass, skinfold thickness) and measures of
growth andneurodevelopment at childhood follow-up; infant fast-
ing C-peptide level at three months; infant C-peptide level one
hour after glucose-amino acid challenge at three months; infant
glucose fasting level at three months; infant glucose level one hour
after glucose-amino acid challenge at threemonths; gestational age
at delivery.
Maternal
Pre-eclampsia; vaginal delivery (spontaneous, ventouse, forceps);
postpartum haemorrhage; severe perineal trauma (third- and
fourth-degree tear), maternal hypoglycaemia and hyperglycaemic
episodes requiring intervention; weight gain in pregnancy; induc-
tionof labour (reasons related todiabetes); breastfeeding; retinopa-
thy; quality of life (psychological impact of management, assessed
by psychometric testing using a reliable standardised question-
naire); women’s preference and satisfactionwith treatment; an eco-
nomic evaluation; ventouse delivery; maternal ketonuria.
5. Insulin Aspart + NPH insulin versus Human insulin
+ NPH insulin (Different insulin types within similar
insulin regimens)
See Summary of findings 5. We included one trial in this compar-
ison (Mathiesen 2007) involving a total of 223 women. This is
an empty ’summary of findings’ table with no evidence or quality
assessment as none of the primary outcomes were included in this
trial.
Primary outcomes
Infant
None reported.
Maternal
None reported.
Secondary outcomes
Infant
None reported.
Maternal
There was very low-quality evidence from one study (223 women)
of no difference between insulin Aspart and human insulin for di-
abetic metabolic control, measured by A1c at third trimester visits
(MD -0.10%, 95% CI -0.28 to 0.08; Analysis 5.1, average plasma
glucose at third trimester visits (MD -0.20 mmol/L, 95% CI -
0.53 to 0.13; Analysis 5.2); and maternal hypoglycaemic episodes
(RR 1.06, 95% CI 0.99 to 1.14; Analysis 5.3);
Outcomes not prespecified in protocol
Infant
None.
Maternal
None.
Outcomes not reported
Infant
Macrosomia; perinatal death; fetal anomaly; birth trauma includ-
ing shoulder dystocia, nerve palsy and fracture; preterm birth less
than 37 weeks; small-for-gestational age at delivery; five-minute
Apgar score less than seven; birthweight centile corrected for ges-
tational age at delivery, parity, ethnicity, maternal weight and fe-
tal sex; admission and length of stay in neonatal intensive care
unit; mechanical ventilation; neonatal infection; neonatal hypo-
glycaemia; insulin sensitivity (cord insulin, C-peptide); jaundice
requiring therapy; respiratory distress syndrome; hyperbilirubi-
naemia; necrotising enterocolitis; intracranial haemorrhage; arti-
ficial (tube) feeding; a composite outcome measure of neonatal
morbidity (admission and length of stay in neonatal intensive care
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unit, mechanical ventilation, neonatal infection, neonatal hypo-
glycaemia, insulin sensitivity (cord insulin, C-peptide), jaundice
requiring therapy, respiratory distress syndrome, hyperbilirubi-
naemia, necrotising enterocolitis, intracranial haemorrhage, arti-
ficial (tube) feeding); neonatal anthropometry (length, head cir-
cumference, ponderal index); neonatal adiposity (fat mass, skin-
fold thickness) and measures of growth and neurodevelopment at
childhood follow-up; birthweight; infant fasting C-peptide level
at three months; infant C-peptide level one hour after glucose-
amino acid challenge at three months; infant glucose fasting level
at three months; infant glucose level one hour after glucose-amino
acid challenge at three months; gestational age at delivery.
Maternal
Caesarean section; pre-eclampsia; vaginal delivery (spontaneous,
ventouse, forceps); postpartum haemorrhage; severe perineal
trauma (third- and fourth-degree tear); weight gain in pregnancy;
induction of labour (reasons related to diabetes); postpartum in-
fection; breastfeeding; retinopathy; quality of life (psychological
impact of management, assessed by psychometric testing using
a reliable standardised questionnaire); use of healthcare resources
(rate of antenatal clinic visits and admission for treatment relating
to diabetic control, ultrasound growth scans, biophysical scans,
dopplers, cardiotocograph’s); women’s preference and satisfaction
with treatment; an economic evaluation; ventouse delivery; ma-
ternal ketonuria; maternal compliance with treatment score (1 =
best, 5 = worst compliance).
6. Insulin Detemir + Aspart versus NPH insulin +
Aspart (Different insulin types within similar insulin
regimens)
See Summary of findings 6. We included one trial in this compar-
ison (Mathiesen 2012) involving a total of 162 women. The evi-
dence for the outcomes supported by this study was downgraded
to very low for study limitations (high or unclear risk of bias for
allocation concealment, blinding of participants and personnel,
incomplete outcome data, selective outcome reporting, and other
biases) and sparse data (one small study, few events for the out-
comes, very wide confidence intervals often crossing the line of no
effect).
Primary outcomes
Infant
None reported.
Maternal
None reported.
Secondary outcomes
Infant
There was very low-quality evidence from one study (162 infants)
of no clear difference in the number of major fetal anomalies in the
insulin Detemir group compared to the NPH insulin group (RR
3.15, 95% CI 0.33 to 29.67; Analysis 6.1), major fetal anoma-
lies (RR 2.10, 95% CI 0.19 to 22.72; Analysis 6.2); minor fetal
anomalies (RR 0.35, 95% CI 0.01 to 8.47; Analysis 6.3), and
minor fetal anomalies (RR 1.05, 95% CI 0.22 to 5.05; Analysis
6.4). Outcome assessors were blinded for Analyses 6.1 and 6.3 and
unblinded for Analyses 6.2 and 6.4.
Maternal
Outcomes not prespecified in protocol
Infant
None.
Maternal
None.
Outcomes not reported
Infant
Macrosomia; perinatal death; birth trauma including shoulder
dystocia, nerve palsy and fracture; pretermbirth less than37weeks;
small-for-gestational age at delivery; five-minute Apgar score less
than seven; birthweight centile corrected for gestational age at
delivery, parity, ethnicity, maternal weight and fetal sex; admis-
sion and length of stay in neonatal intensive care unit; mechan-
ical ventilation; neonatal infection; neonatal hypoglycaemia; in-
sulin sensitivity (cord insulin, C-peptide); jaundice requiring ther-
apy; respiratory distress syndrome; hyperbilirubinaemia; necrotis-
ing enterocolitis; intracranial haemorrhage; artificial (tube) feed-
ing; a composite outcome measure of neonatal morbidity (admis-
sion and length of stay in neonatal intensive care unit, mechan-
ical ventilation, neonatal infection, neonatal hypoglycaemia, in-
sulin sensitivity (cord insulin, C-peptide), jaundice requiring ther-
apy, respiratory distress syndrome, hyperbilirubinaemia, necrotis-
ing enterocolitis, intracranial haemorrhage, artificial (tube) feed-
ing); neonatal anthropometry (length, head circumference, pon-
deral index); neonatal adiposity (fat mass, skinfold thickness) and
measures of growth and neurodevelopment at childhood follow-
up; birthweight; infant fasting C-peptide level at three months;
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infant C-peptide level one hour after glucose-amino acid challenge
at three months; infant glucose fasting level at three months; in-
fant glucose level one hour after glucose-amino acid challenge at
three months; gestational age at delivery.
Maternal
Caesarean section; pre-eclampsia; vaginal delivery (spontaneous,
ventouse, forceps); postpartum haemorrhage; severe perineal
trauma (third- and fourth-degree tear); measures of diabetic
metabolic control (levels of HbA1c, daily mean self-monitored
blood glucose, post-prandial and fasting, continuous glucosemon-
itoring); maternal hypoglycaemia and hyperglycaemic episodes
requiring intervention; weight gain in pregnancy; induction of
labour (reasons related to diabetes); postpartum infection; breast-
feeding; retinopathy; quality of life (psychological impact of man-
agement, assessed by psychometric testing using a reliable stan-
dardised questionnaire); use of healthcare resources (rate of ante-
natal clinic visits and admission for treatment relating to diabetic
control, ultrasound growth scans, biophysical scans, dopplers, car-
diotocograph’s); women’s preference and satisfaction with treat-
ment; an economic evaluation; ventouse delivery; maternal ke-
tonuria; maternal compliance with treatment score (1 = best, 5 =
worst compliance).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Human insulin versus animal insulin (Different insulin types within similar insulin regimens)
Patient or population: pregnant women with pre-exist ing diabetes
Setting: The Children’s Hospital of San Francisco and Cornell University Medical College, New York
Intervention: human insulin (recombinant deoxyribonucleic acid - Humulin)
Comparison: animal insulin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with animal in-
sulin
Risk with human in-
sulin (Humulin)
Macrosomia Study populat ion RR 0.22
(0.01 to 4.30)
42
(1 RCT)
⊕©©©
VERY LOW 1234
91 per 1000 20 per 1000
(1 to 391)
Perinatal death (0 studies) Not reported
Pre-eclampsia (0 studies) Not reported
Caesarean sect ion (0 studies) Not reported
Fetal anomaly (0 studies) Not reported
Birth trauma includ-
ing shoulder dystocia,
nerve palsy, and f rac-
ture
(0 studies) Not reported
Composite outcome
measure of neonatal
morbidity
(0 studies) Not reported
2
9
D
iffe
re
n
t
in
su
lin
ty
p
e
s
a
n
d
re
g
im
e
n
s
fo
r
p
re
g
n
a
n
t
w
o
m
e
n
w
ith
p
re
-e
x
istin
g
d
ia
b
e
te
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias was high or unclear for random sequence generat ion, allocat ion concealment, blinding of part icipants and
personnel, blinding of outcome assessment, incomplete outcome data, and select ive outcome report ing
2 One study with serious design lim itat ions including lack of blinding for allocat ion concealment
3 Very wide 95% conf idence intervals crossing the line of no ef fect
4 Small sample size and few events
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Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Patient or population: pregnant women with pre-exist ing diabetes
Setting: University of M ississippi Medical Centre, USA
Intervention: pre-mixed insulin (70 NPH/ 30 REG)
Comparison: self -m ixed split dose insulin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with self-mixed
split dose insulin
Risk with pre-mixed in-
sulin (70 NPH/30 REG)
Macrosomia Study populat ion RR 0.49
(0.09 to 2.54)
93
(1 RCT)
⊕©©©
VERY LOW 1,2,3
87 per 1000 43 per 1000
(8 to 221)
Perinatal death (0 studies) Not reported
Pre-eclampsia (0 studies) Not reported
Caesarean sect ion 4 Study populat ion RR 0.57
(0.25 to 1.32)
93
(1 RCT)
⊕©©©
VERY LOW 123
261 per 1000 149 per 1000
(65 to 344)
Fetal anomaly (0 studies) Not reported
Birth trauma includ-
ing shoulder dystocia,
nerve palsy, or f racture
(0 studies) Not reported
Composite outcome
measure of neonatal
morbidity
(0 studies) Not reported
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Very wide 95% conf idence intervals crossing the line of no ef fect
2 Small sample size and few events
3 One study with serious design lim itat ions
4 Caesarean sect ion for cephalo-pelvic disproport ion
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Insulin injected with a Novolin pen versus insulin injected with a needle or syringe (Different insulin regimens with similar insulin types used within the regimen)
Patient or population: pregnant women with pre-exist ing diabetes
Setting: University of M ississippi Medical Centre, USA
Intervention: insulin injected with a Novolin pen
Comparison: insulin injected with a needle or syringe
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with insulin in-
jected with a needle or
syringe
Risk with insulin in-
jected with a Novolin
pen
Macrosomia Study populat ion RR 0.21
(0.03 to 1.76)
93
(1 RCT)
⊕©©©
VERY LOW 1,2,3
104 per 1000 22 per 1000
(3 to 183)
Perinatal death (0 studies) Not reported
Pre-eclampsia (0 studies) Not reported
Caesarean sect ion 4 Study populat ion RR 0.38
(0.15 to 0.97)
93
(1 RCT)
⊕©©©
VERY LOW 1,2,3
292 per 1000 111 per 1000
(44 to 283)
Fetal anomaly (0 studies) Not reported
Birth trauma includ-
ing shoulder dystocia,
nerve palsy, or f racture
(0 studies) Not reported
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Composite outcome
measure of neonatal
morbidity
(0 studies) Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Very wide 95% conf idence intervals crossing the line of no ef fect
2 Small sample size with few events
3 One study with serious design lim itat ions
4 Caesarean sect ion for cephalo-pelvic disproport ion
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Insulin Aspart (+ NPH) compared to human insulin (+ NPH) for pregnant women with pre-existing diabetes (Different insulin types within similar insulin regimens)
Patient or population: pregnant women with pre-exist ing diabetes
Setting: 63 dif ferent sites in 18 countries
Intervention: insulin Aspart (+ NPH insulin)
Comparison: human insulin (+ NPH insulin)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with human in-
sulin (+ NPH)
Risk with insulin Aspart
(+ NPH)
Macrosomia - - - - - Not reported
Perinatal death - - - - - Not reported
Pre-eclampsia - - - - - Not reported
Caesarean sect ion - - - - - Not reported
Fetal anomaly - - - - - Not reported
Birth trauma includ-
ing shoulder dystocia,
nerve palsy and f rac-
ture
- - - - - Not reported
Composite outcome
measure of neonatal
morbidity
- - - - - Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Different insulin types within similar insulin regimens)
Patient or population: pregnant women with pre-exist ing diabetes
Setting: 79 sites in 17 countries, mainly within Europe
Intervention: insulin Detemir (+ Aspart)
Comparison: NPH (+ Aspart)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with NPH (+ As-
part)
Risk with insulin De-
temir (+ Aspart)
Macrosomia (0 studies) Not reported
Perinatal death (0 studies) Not reported
Pre-eclampsia (0 studies) Not reported
Caesarean sect ion (0 studies) Not reported
Fetal anomaly (major) 1 Study populat ion RR 3.15
(0.33 to 29.67)
162
(1 RCT)
⊕©©©
VERY LOW 2,3,4,5
12 per 1000 38 per 1000
(4 to 357)
Birth trauma includ-
ing shoulder dystocia,
nerve palsy, or f racture
(0 studies) Not reported
Composite outcome
measure of neonatal
morbidity
(0 studies) Not reported
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Assessed by an expert who was blinded to the outcome
2 One study with design lim itat ions
3 Very wide 95% conf idence intervals crossing the line of no ef fect
4 Large ef fect est imate
5 Small sample size with few events
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D I S C U S S I O N
There are many different types of insulin (e.g. human, animal),
and many different insulin regimens (e.g. injection of insulin via a
pen or injection of insulin with a conventional needle or syringe).
This review sought to investigate whether any particular type of
insulin or any particular regimen was safer or more effective for
improving maternal and fetal health and well-being in pregnant
women with pre-existing type 1 or type 2 diabetes.
Summary of main results
This review included five trials, with a total of 554 women and
554 babies. We could not determine whether there were any clear
differences for the primary infant outcomes (macrosomia and peri-
natal death) or primary maternal outcomes (caesarean section and
pregnancy-induced hypertension or pre-eclampsia) for each of the
comparisons of different insulin types (Lispro versus regular in-
sulin Summary of findings for the main comparison; Human in-
sulin versus animal insulin Summary of findings 2; Insulin As-
part versus human insulin Summary of findings 5; and Insulin
Detemir versus NPH insulin Summary of findings 6), or for the
different insulin regimens (Pre-mixed insulin versus self-mixed in-
sulin Summary of findings 3; and Insulin injected with a Novolin
pen versus insulin injected with a conventional needle or syringe
Summary of findings 4), since many were not reported in the tri-
als, and secondly, where they were reported, the data were from a
single, small trial. There were also no clear differences found for
the secondary infant and maternal outcomes. In one trial, human
insulin was associated with a lower mean insulin requirement dur-
ing pregnancy, compared with the animal insulin group. In an-
other trial, pre-mixed insulin was associated with a lower antepar-
tum capillary glucose measurement two hours postprandial (af-
ter lunch) when compared with self-mixed insulin. The same was
found when theNovolin pen was compared with the conventional
needle or syringe. In addition, there were fewer caesarean sections
in the Novolin pen group compared with the conventional needle
or syringe group. Many important outcomes were not reported
in these trials including most primary outcomes and secondary
infant and maternal outcomes. There was no long-term follow-up
of infants in these studies, and information on healthcare use and
satisfaction with insulin treatments was lacking.
Overall completeness and applicability of
evidence
Overall, we only included five trials in this review that included
pregnant womenwith pre-existing diabetes. It was difficult to draw
any firm conclusions from the trials, or to say that they were gen-
eralisable to the general pregnant population for many reasons.
First of all, the sample sizes in the trials were small. Second, many
of the review’s primary prespecified outcomes were not reported,
for example, perinatal death and pre-eclampsia were each reported
in only one trial, and macrosomia and caesarean section were each
reported in only two trials. Further trials in pregnant women are
required that are adequately powered, and that report all outcomes
suggested in this review, to evaluate the different insulin types and
regimens.
Quality of the evidence
The trials included in this reviewwere small. Overall, the quality of
reporting was poor, and therefore, risk of bias in all trials was either
high or unclear. All of the trials were open trials, as it is difficult
to blind participants or clinicians to the intervention allocation
in trials such as those included in this review. However, outcome
assessors could have been blinded but were not in the majority of
the trials.Wedonot know if the pregnantwomen included in these
trials were representative of the general population of women with
pre-existing type 1 or type 2 diabetes, but researchers should try
to ensure that their trial populations reflect the general obstetric
population as much as possible.
Most primary outcomes were not reported. For those that were
reported, our GRADE assessment was that the quality of the evi-
dence was very low (caesarean section, pregnancy-induced hyper-
tension or pre-eclampsia, fetal anomaly, birth trauma, and macro-
somia). This was because there was only a single study for each
comparison, so pooling of the data was not possible, there were
design limitations in the included trials (high or unclear risk of bias
for allocation concealment, blinding of participants and person-
nel, blinding of outcome assessment, incomplete outcomedata, se-
lective outcome reporting and other biases) and sparse data (small
sample sizes, wide confidence intervals that crossed the line of
no effect, and few or no events). These judgements are shown in
the Summary of findings for the main comparison, Summary of
findings 2, Summary of findings 3, Summary of findings 4, and
Summary of findings 6. We were unable to populate Summary
of findings 5, because our primary outcomes were not reported
for this comparison. Therefore, we could not conclude whether
one type of insulin or one insulin regimen was better in pregnant
women with pre-existing diabetes for improving maternal and in-
fant outcomes.
Potential biases in the review process
Risk of bias assessment is a subjective process. This can be min-
imised by following the procedures outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
whereby two or more review authors independently assess stud-
ies and resolve any disagreement through discussion, involving a
third assessor to reach consensus as required. In this review, we
undertook a comprehensive and systematic search of databases to
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Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
reduce the potential for publication bias, and did not apply any
language, date, or publication status restrictions.
Agreements and disagreements with other
studies or reviews
Our findings, that the limited number of trials that provided very
low-quality evidence, restricted us from drawing any meaningful
or scientific conclusions regarding the safety and effectiveness of
one type of insulin over the other, or one insulin regimen over
the other, in pregnant women with pre-existing type 1 or type
2 diabetes. This was also the case in other reviews (Farrar 2016;
Horvath 2007; Siebenhofer 2006). All reported that there was no
evidence of any clear benefit of one insulin type or regimen over
the other, and that large, randomised trials of better methodolog-
ical quality are required. One review found that long-acting in-
sulin preparations seemed to have a beneficial effect on nocturnal
glucose levels; their overall diabetes control was described as clini-
cally unremarkable (Vardi 2008). This review included three very
large randomised controlled trials but concluded that the findings
warranted further substantiation. This review was not in pregnant
women.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present, insufficient data exist to allow the review authors to
make any substantial or concrete conclusions about the effective-
ness of one insulin type or regimen over another in pregnant
women with pre-existing type 1 or type 2 diabetes. Therefore,
decisions about the use of different types of insulin and different
insulin regimens for pregnant women with pre-existing type 1 or
type 2 diabetes should be made according to individual needs and
available resources.
Implications for research
Large, multi-centred trials, which are adequately randomised, suf-
ficiently powered, and clearly reported are needed to assess the
safety and effectiveness of different insulin types and regimens in
pregnant women with pre-existing type 1 or type 2 diabetes. It
would be very helpful if outcomes across trials were consistently
defined and reported. In addition, it is difficult to blind women
and caregivers to their randomised allocation because of the na-
ture of the intervention of interest. However, it is possible to blind
the outcome assessor to treatment allocation, which is strongly
recommended. Any blinding should be clearly stated in the trial
report. Future trials should undertake a longer period of follow-
up of women and their infants, as well as the cost-effectiveness of
various insulin types and regimens.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Jovanovic-Peterson 1992
Methods RCT (open-label, 2-centre, 2-arm).
Participants 43 insulin-requiring pregnant women with diabetes (type 1 or 2)
Recruited between 1983 and 1985.
Setting: The Children’s Hospital of San Francisco and Cornell University Medical Col-
lege, New York
Inclusion criteria: pregnant women with type 1 or 2 diabetes; < 20 weeks’ gestation; aged
> 18 years old; treated with animal insulin for at least 24 months; bodyweight within
20% of ideal body weight as determined by the Metropolitan Life tables
Exclusion criteria: women with hypertension (blood pressure > 140/90 mmHg); serum
creatine higher than the upper range of normal; advanced cardiovascular disease; history
of Addison’s disease or pituitary insufficiency; local or systemic allergy to animal source
insulin; pre-pregnancy insulin dose greater than 1.5 U/kg per 24 hours, history of treat-
ment human insulin or an insulin infusion device
Interventions Human insulin (recombinant deoxyribonucleic acid - Humulin); N = 20
Outcomes Infant
Gestational age at delivery
Percentile body weight
Skinfold thickness
Length
Weight
Head circumference
Large-for-gestational age at delivery
Small-for-gestational age at delivery
C-peptide level (pmol/mL)
Glucose level (mmol)
Preterm delivery
Appropriate-for-gestational age at delivery
Macrosomia (birthweight > 4000 g)
Maternal
Temperature
Systolic blood pressure
Diastolic blood pressure
Resting heart rate
Edema
Renal function
Complete blood cell count
Chemistry profile
Calories consumed
Weight gain
Glycohemoglobin levels
Maternal ketonuria
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Jovanovic-Peterson 1992 (Continued)
Mean insulin dose requirement
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Women were randomly assigned to treatment
with either human or their current animal insulin.
However, there was no description of the method
used
Allocation concealment (selection bias) High risk Open-label trial.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel: no. Open-label trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1woman (out of 23) randomised to the animal in-
sulin group did not complete the admission visit
or return for follow-up. Shewas excluded from the
statistical analysis. Not all babies were included
in the reporting of large-for-gestational age at de-
livery
Selective reporting (reporting bias) Unclear risk This studywas assessed from the published report.
No protocol was available, so we do not know if
all pre-specified outcomes were reported
Other bias Low risk It was reported that the baseline characteristics of
groups showed a remarkably similar population
of women in both groups
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Mathiesen 2007
Methods 2 arm RCT (open-label, parallel group, multi-centre).
Participants Setting: 63 sites in 18 countries, mainly within Europe.
Inclusion criteria: women ≥ 18 years with insulin-treated type 1 diabetes for ≥ 12
months. Women were either pregnant with a singleton pregnancy (gestational age at
delivery≤ 10 weeks; N = 223, included in this review), or planning to become pregnant
(N = 99, excluded from this review). A1c was ≤ 8% at confirmation of pregnancy
Exclusion criteria: women with multiple pregnancy, fertility treatment, clinically sig-
nificant gynaecological conditions, diabetic nephropathy or medical problems, a previ-
ous child born with major congenital malformations, multiple miscarriage, or stillbirths
(more than 2). Women not pregnant within 12 months of randomisation
Interventions Experimental: prandial insulin Aspart (100 units/mL: Novo Nordisk, Basvaerd, Den-
mark) + NPH insulin. 1 to 4 subcutaneous injections per day (lowest available at centre)
using the Novo pen. N = 113 (randomised when pregnant)
Comparison: prandial human insulin (100 IU/mL; Novo Nordisk) + NPH insulin. 1 to
4 subcutaneous injections per day (lowest available at centre) using the Novo pen. N =
110 (randomised when pregnant)
Outcomes Many outcomeswere reported for all women in the study:major hypoglycaemia requiring
third-party assistance, minor hypoglycaemia, maternal death, hypoglycaemic coma, in-
adequate glycaemic control, hyperglycaemia, pre-eclampsia, preterm labour, emergency
caesarean section, glycaemic control, A1c, plasma glucose profile breakfast, lunch, din-
ner, mean insulin dose), abortion, caesarean section, induced abortion, stillbirth, QoL
assessments
However, few of these were reported separately for women randomised during pregnancy
Notes SON contacted the authors to request additional data. A web site link was received, but
did not allow access to the data. We received no responses to further requests
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States that women were ’randomised’, but
no further description of method was given
Allocation concealment (selection bias) Unclear risk No description.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel: no. Open-label trial.
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Mathiesen 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All women in the subgroup included in
the review were accounted for. Women
who were not pregnant ≤ 12 months after
randomisation were withdrawn from the
study: potential bias in conception rates be-
tween groups affected the overall study, but
not the subgroup included in the review
Selective reporting (reporting bias) High risk Very few outcomes were reported for the
subgroup of women who were randomised
during pregnancy
Other bias Unclear risk The report declared that the trial was spon-
sored by Novo Nordisk. It was unclear
whether this conflict of interest introduced
any bias
Mathiesen 2012
Methods 2-arm RCT, open label, parallel group, multi-centre.
Participants Setting: 79 different sites in 17 countries.
Inclusion criteria: Women ≥ 18 years with insulin-treated type 1 diabetes for ≥ 12
months before randomisation. They were either pregnant with a singleton pregnancy
(gestational age at delivery 8 to 12 weeks; N = 162, included in this review), or planning
to become pregnant (N =148, excluded from this review). A1c was≤ 8% at confirmation
of pregnancy
Exclusion criteria: women with impaired hepatic or renal function or uncontrolled hy-
pertension (systolic blood pressure≥ 140 mmHg, diastolic blood pressure≥ 90 mmHg,
or both), undergoing medical infertility treatment, or who had been previously ran-
domised in this trial. Women not pregnant within 12 months of randomisation
Interventions Experimental intervention: Insulin Detemir (100 units/mL) with prandial insulin Aspart
(100 units/mL) in a basal bolus regimen (1:1), subcutaneous injections administered
from randomisation until termination or 6 weeks postdelivery. N = 79 (randomised
when pregnant)
Control/Comparison intervention: NPH insulin (100 IU/mL) with prandial insulin As-
part (100 units/mL) in a basal bolus regimen (1:1), subcutaneous injections adminis-
tered from randomisation until termination or 6weeks postdelivery.N = 83 (randomised
when pregnant)
Basal insulin dose was titrated according to fasting or pre-dinner capillary plasma glucose
values. All bolus insulin doses were titrated according to pre- and postprandial plasma
glucose values. Preprandial PG target of 72 to 108 mg/dL (4.0-6.0 mmol/L) and 2-hour
postprandial glucose target < 126 mg/dL (< 7.0 mmol/L)
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Mathiesen 2012 (Continued)
Outcomes Many outcomes were reported for all women in the study: hypoglycaemia, glycaemic
control including A1c, insulin dose, adverse events, pregnancy outcomes
However, few of these were reported separately for women randomised during pregnancy
Notes SON contacted the authors to request additional data. A web site link was received, but
did not allow access to the data. We received no responses to further requests
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Low risk “Subjects were randomised 1:1 (using In-
teractive Voice/Web Response System).“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk .Personnel: no. Open-label trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Open-label. Congenital malformations
were assessed by 2 independent experts, 1
of whom was blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All women in the subgroup included in
the review were accounted for. Women
who were not pregnant ≤ 12 months after
randomisation were withdrawn from the
study: potential bias in conception rates be-
tween groups affected the overall study, but
not the subgroup included in the review
Selective reporting (reporting bias) High risk Very few outcomes were reported for the
subgroup of women who were randomised
during pregnancy
Other bias Unclear risk The report declared that the trial was spon-
sored by Novo Nordisk. It was unclear
whether this conflict of interest introduced
any bias
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Persson 2002
Methods RCT (open-label, multi-centre, 2-arm).
Participants 33 pregnant women with type 1 diabetes recruited at 6 to 8 weeks’ gestation and entered
into the study at 15 weeks’ gestation
Setting: 4 centres in Sweden. The Departments of Obstetrics and Gynaecology in Hud-
dingeHospital, KarolinskaHospital, Södersjukhuset in Stockholm, andÖrebroRegional
Hospital
Inclusion criteria: pregnant women with type 1 diabetes; duration of diabetes for a
minimum of 2 years; aged 20 years or more; multiple dose regimen with regular and
NPH insulin; Initial HbA1c value below 9%
Exclusion criteria: gestational or type 2 diabetes; duration of diabetes less than 2 years;
aged younger than 20 years; In receipt of insulin lispro (intervention); HbA1c value
greater than 9%
Interventions Preprandial rapid-acting insulin lispro (Humalog®) in combination with NPH in a
MDI regimen with administration of lispro or regular insulin immediately before or 30
minutes before meals, respectively. Medium-acting NPH insulin was administered at
bedtime and when needed before breakfast. All women were given dietary instruction
by a dietician. Blood glucose targets were pre- and postprandial levels of < 5.0 and < 6.
5 mmol/l respectively. N = 16
Outcomes Infant
Gestational age at delivery
Birthweight
Length
Appropriate-for-gestational age at delivery
Small-for-gestational age at delivery
Large-for-gestational age at delivery
Malformation
Birth trauma
Asphyxia
Respiratory distress
Hypoglycaemia
Hyperbilirubinemia
Perinatal death
Maternal
Micoangiopathy
Glycaemic control (HbA1c
,
blood glucose, hypoglycaemia)
Retinopathy
Mode of delivery
Hypertension
Pre-eclampsia
Polyhydamniosis
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Persson 2002 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was conducted at a cen-
tral site according to 4-patient block model
(AABB, etc.)
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel: no. Open-label trial.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The report indicated that 7 women did not
satisfy the inclusion criteria and 2 were un-
willing to participate. These appeared to be
in addition to those randomised, but it was
unclear if these women were randomised and
then withdrawn from the study
Selective reporting (reporting bias) High risk The trial was assessed from the published re-
port, with no protocol available. It was not
clear whether all prespecified outcomes were
reported. Some outcomes were described as
showing no differences, but these figures were
not given: gestational age at delivery, birth-
weight, rate of large-for-gestational-age in-
fants, neonatal complications
Other bias Unclear risk It was reported that there were no significant
differences between the 2 treatment groups
with regard to baseline characteristics, how-
ever, significantly more women in the lispro
group had aneurysms
Schuster 1998
Methods RCT (single-blinded, 1 centre, 4-arm).
Participants 93 pregnant women with type 1 or 2 diabetes.
Setting: University of Mississippi Medical Centre, USA.
Inclusion criteria: insulin-dependent diabetes; maternal age 15 to 44 years; < 20 weeks’
gestation at entry; willingness to sign an informed consent form
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Schuster 1998 (Continued)
Exclusion criteria: additional pregnancy complications which might affect maternal or
infant outcome (hypertension, placenta praevia, fetal malformations, and glucose intol-
erance not requiring insulin); unwillingness to comply with prenatal care or aggressive
glucose control; women’s refusal to participate
Interventions Women were enrolled into 4 groups.
Intervention 1: pre-mixed insulin (70 NPH/30 REG) administered with a needle or
syringe (N = 24)
Intervention 2: self-mixed split dose regular and NPH insulin administered with a No-
volin® pen (N = 22)
Intervention 3: pre-mixed insulin (70 NPH/30 REG) administered with a Novolin®
pen (N = 23)
Control: self-mixed split dose regular and NPH insulin administered with a needle or
syringe (N = 24)
Outcomes Infant
Gestational age at delivery
Preterm delivery
Infant birthweight
Macrosomia
1- and 5-minute Apgar score
Hyperbilirubinemia
Hypoglycaemia
Hypocalcemia
Incidence of admission to the neonatal unit
Maternal
Caesarean delivery for cephalo-pelvic disproportion
Pregnancy-induced hypertension
Capillary glucose measurements (mg/DL)
Abruption
Chorioamnionitis
Endometritis
Maternal hospital days
Number of prenatal visits
Overall patient compliance (based on dietary assessment, adequate glucose monitoring,
insulin usage, appropriate follow-up with physician instructions, and visits) scored from
1 to 5, with 1 implying good compliance and 5 implying poor compliance
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out by selecting
an opaque, consecutively-numbered envelope
in which computer-generated randomisation
cards were placed, to assign women into 1 of
4 groups
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Schuster 1998 (Continued)
Allocation concealment (selection bias) Low risk Randomisation was carried out by selecting
an opaque, consecutively-numbered envelope
in which computer-generated randomisation
cards were placed, to assign women into 1 of
4 groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Personnel: yes. Staff managing the women
were unaware of the treatment regimen to
which the women were assigned, during the
antepartum period
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 100 women enrolled, 93 were available
for outcome analysis. 2 women suffered spon-
taneous abortions, 2 underwent elective ter-
minations and 3 were lost to follow-up. These
7womenwere equally distributed between the
4 groups
Selective reporting (reporting bias) Unclear risk This trial was assessed from the published re-
port, with no protocol available. It was not
clear whether all prespecified outcomes were
reported. Some outcomes were described as
showing no differences, but the figures were
not given: caesarean section for any indica-
tion, incidence of pregnancy-induced hyper-
tension, preterm labour, infant hyperbiliru-
binaemia, and hypoglycaemia. It was unclear
whether caesarean section for cephalo-pelvic
disproportion was a pre-specified outcome, or
included because it showed a significant dif-
ference between groups
Other bias Low risk There were no significant differences between
the treatment groups with regard to baseline
characteristics
RCT: randomised controlled trial
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Carr 2004 Cross-over trial design.
Herrera 2015b Included women with gestational diabetes.
Kipikasa 2008 Included women with gestational diabetes.
Mohd 2012 Included women with gestational diabetes.
Murphy 2011 Cross-over trial design.
Nachum 1999 Included women with gestational diabetes.
Nor 2007 Included women with gestational diabetes.
Porta 2011 Did not include the intervention: randomisation prior to pregnancy
Reller 1985 Did not include the intervention: not a randomised controlled trial
Secher 2012 Did not include the intervention: a trial of glucose monitoring not insulin regimen
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D A T A A N D A N A L Y S E S
Comparison 1. Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal death 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Caesarean section 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.25, 1.39]
3 Pregnancy-induced hypertension
and pre-eclampsia
1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.35, 1.30]
4 Fetal anomaly 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.02, 8.08]
5 Birth trauma, including shoulder
dystocia, nerve palsy, and
fracture
1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Vaginal delivery (spontaneous,
ventouse, forceps)
1 33 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.80, 2.67]
7 Blood glucose (mmol/L) week
14 (after lunch)
1 33 Mean Difference (IV, Fixed, 95% CI) -1.09 [-3.60, 1.42]
8 Blood glucose (mmol/L) weeks
21, 28, and 34 combined (after
lunch)
1 33 Mean Difference (IV, Fixed, 95% CI) -0.04 [-2.10, 2.02]
9 Postprandial increase of blood
glucose (mmol/L) before week
14 (lunch)
1 33 Mean Difference (IV, Fixed, 95% CI) 1.0 [-1.52, 3.52]
10 Postprandial increase of blood
glucose (mmol/L) during weeks
21, 28, and 34 combined
(lunch)
1 33 Mean Difference (IV, Fixed, 95% CI) 0.10 [-2.12, 2.32]
11 Maternal hypoglycaemia
and hyperglycaemia episodes
requiring intervention
1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.10]
12 Retinopathy 1 33 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.17, 6.67]
13 Ventouse delivery 1 33 Risk Ratio (M-H, Fixed, 95% CI) 3.19 [0.37, 27.58]
Comparison 2. Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different
insulin types within similar insulin regimens)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Small-for-gestational age at
delivery
1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Preterm birth (< 37 weeks) 1 42 Risk Ratio (M-H, Fixed, 95% CI) 7.67 [0.42, 139.83]
3 Birthweight centile (%) 1 42 Mean Difference (IV, Fixed, 95% CI) -6.70 [-23.64, 10.
24]
4 Infant length (cm) 1 42 Mean Difference (IV, Fixed, 95% CI) -3.30 [-6.74, 0.14]
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5 Skinfold thickness (mm) 1 42 Mean Difference (IV, Fixed, 95% CI) -4.10 [-13.28, 5.08]
6 Body weight percentile (%) 1 42 Mean Difference (IV, Fixed, 95% CI) -6.70 [-23.74, 10.
34]
7 Head circumference (cm) 1 42 Mean Difference (IV, Fixed, 95% CI) -5.10 [-9.52, -0.68]
8 Macrosomia 1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 4.30]
9 Insulin requirement during
pregnancy (U/kg/24 hour)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.33 [-0.45, -0.21]
10 Birthweight (g) 1 42 Mean Difference (IV, Fixed, 95% CI) -591.0 [-1066.27, -
115.73]
11 Infant fasting C-peptide level
at 3 months (pmol/mL)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.13, -0.01]
12 Infant C-peptide level 1
hour after glucose-amino
acid challenge at 3 months
(pmol/mL)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.19, -0.03]
13 Infant glucose fasting level at 3
months (pmol/mL)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.62, 0.22]
14 Infant glucose level 1 hour after
glucose-amino acid challenge at
3 months (pmol/mL)
1 42 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.04, 1.04]
15 Gestational age at delivery
(weeks)
1 42 Mean Difference (IV, Fixed, 95% CI) 0.5 [-3.70, 4.70]
16 Maternal ketonuria 1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.08, 1.61]
Comparison 3. Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin
regimens with similar insulin types used within the regimen)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Macrosomia 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.54]
2 Caesarean section 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.25, 1.32]
3 Antepartum capillary glucose
measurement (mg/dL), 2 hours
postprandial (after lunch)
1 10218 Mean Difference (IV, Fixed, 95% CI) -11.25 [-12.55, -9.
95]
4 Postpartum infection:
endometritis
1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.26, 1.04]
5 Use of healthcare resources
(maternal hospital days)
1 94 Mean Difference (IV, Fixed, 95% CI) -0.50 [-1.40, 0.41]
6 Birthweight (g) 1 93 Mean Difference (IV, Fixed, 95% CI) -116.56 [-391.81,
158.69]
7 Compliance score 1 49 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.87, 0.87]
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Comparison 4. Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Different
insulin regimens with similar insulin types used within the regimen)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Macrosomia 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.03, 1.76]
2 Caesarean section 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.15, 0.97]
3 Antepartum capillary glucose
measurement (mg/dL) 2 hours
postprandial (after lunch)
1 10218 Mean Difference (IV, Fixed, 95% CI) -7.23 [-8.51, -5.95]
4 Postpartum infection:
endometritis
1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.28, 1.14]
5 Use of healthcare resources
(maternal hospital days)
1 93 Mean Difference (IV, Fixed, 95% CI) -0.56 [-1.45, 0.33]
6 Birthweight (g) 1 93 Mean Difference (IV, Fixed, 95% CI) -162.36 [-438.25,
113.53]
7 Compliance score 1 93 Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.83, 0.41]
Comparison 5. Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Different insulin types within
similar insulin regimens)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 A1c (%) third trimester visit 1 223 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.28, 0.08]
2 Average plasma glucose
(mmol/L) third trimester visit
1 223 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.53, 0.13]
3 Maternal hypoglycaemic
episodes
1 223 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.99, 1.14]
Comparison 6. Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Different
insulin types within similar insulin regimens)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major congenital malformation 1 162 Risk Ratio (M-H, Fixed, 95% CI) 3.15 [0.33, 29.67]
2 Major congenital malformation 1 162 Risk Ratio (M-H, Fixed, 95% CI) 2.10 [0.19, 22.72]
3 Minor congenital malformation 1 162 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.47]
4 Minor congenital malformation 1 162 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.22, 5.05]
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Analysis 1.1. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 1 Perinatal death.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 1 Perinatal death
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 0/16 0/17 Not estimable
Total (95% CI) 16 17 Not estimable
Total events: 0 (Lispro insulin), 0 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Lispro Favours Regular insulin
Analysis 1.2. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 2 Caesarean section.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 2 Caesarean section
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 5/16 9/17 100.0 % 0.59 [ 0.25, 1.39 ]
Total (95% CI) 16 17 100.0 % 0.59 [ 0.25, 1.39 ]
Total events: 5 (Lispro insulin), 9 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours Lispro Favours Regular insulin
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Analysis 1.3. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 3 Pregnancy-induced hypertension and pre-eclampsia.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 3 Pregnancy-induced hypertension and pre-eclampsia
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 7/16 11/17 100.0 % 0.68 [ 0.35, 1.30 ]
Total (95% CI) 16 17 100.0 % 0.68 [ 0.35, 1.30 ]
Total events: 7 (Lispro insulin), 11 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours Lispro Favours Regular insulin
Analysis 1.4. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 4 Fetal anomaly.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 4 Fetal anomaly
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 0/16 1/17 100.0 % 0.35 [ 0.02, 8.08 ]
Total (95% CI) 16 17 100.0 % 0.35 [ 0.02, 8.08 ]
Total events: 0 (Lispro insulin), 1 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours Lispro Favours Regular insulin
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Analysis 1.5. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 5 Birth trauma, including shoulder dystocia, nerve palsy, and fracture.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 5 Birth trauma, including shoulder dystocia, nerve palsy, and fracture
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 0/16 0/17 Not estimable
Total (95% CI) 16 17 Not estimable
Total events: 0 (Lispro insulin), 0 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Lispro Favours Regular insulin
Analysis 1.6. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 6 Vaginal delivery (spontaneous, ventouse, forceps).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 6 Vaginal delivery (spontaneous, ventouse, forceps)
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 11/16 8/17 100.0 % 1.46 [ 0.80, 2.67 ]
Total (95% CI) 16 17 100.0 % 1.46 [ 0.80, 2.67 ]
Total events: 11 (Lispro insulin), 8 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours Lispro Favours Regular insulin
61Different insulin types and regimens for pregnant women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 7 Blood glucose (mmol/L) week 14 (after lunch).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 7 Blood glucose (mmol/L) week 14 (after lunch)
Study or subgroup Lispro insulin Regular insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Persson 2002 16 6.24 (3.2) 17 7.33 (4.12) 100.0 % -1.09 [ -3.60, 1.42 ]
Total (95% CI) 16 17 100.0 % -1.09 [ -3.60, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Lispro Favours Regular insulin
Analysis 1.8. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 8 Blood glucose (mmol/L) weeks 21, 28, and 34 combined (after lunch).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 8 Blood glucose (mmol/L) weeks 21, 28, and 34 combined (after lunch)
Study or subgroup Lispro insulin Regular insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Persson 2002 16 6.71 (2.83) 17 6.75 (3.2) 100.0 % -0.04 [ -2.10, 2.02 ]
Total (95% CI) 16 17 100.0 % -0.04 [ -2.10, 2.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Lispro Favours Regular insulin
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Analysis 1.9. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 9 Postprandial increase of blood glucose (mmol/L) before week 14 (lunch).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 9 Postprandial increase of blood glucose (mmol/L) before week 14 (lunch)
Study or subgroup Lispro insulin Regular insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Persson 2002 16 1.07 (4.3) 17 0.07 (2.9) 100.0 % 1.00 [ -1.52, 3.52 ]
Total (95% CI) 16 17 100.0 % 1.00 [ -1.52, 3.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Lispro Favours Regular insulin
Analysis 1.10. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 10 Postprandial increase of blood glucose (mmol/L) during weeks 21, 28, and 34
combined (lunch).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 10 Postprandial increase of blood glucose (mmol/L) during weeks 21, 28, and 34 combined (lunch)
Study or subgroup Lispro insulin Regular insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Persson 2002 16 0.7 (3.16) 17 0.6 (3.34) 100.0 % 0.10 [ -2.12, 2.32 ]
Total (95% CI) 16 17 100.0 % 0.10 [ -2.12, 2.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Lispro Favours Regular insulin
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Analysis 1.11. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 11 Maternal hypoglycaemia and hyperglycaemia episodes requiring intervention.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 11 Maternal hypoglycaemia and hyperglycaemia episodes requiring intervention
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 (1) 0/16 2/17 100.0 % 0.21 [ 0.01, 4.10 ]
Total (95% CI) 16 17 100.0 % 0.21 [ 0.01, 4.10 ]
Total events: 0 (Lispro insulin), 2 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Lispro Favours Regular insulin
(1) Authors did not state that intervention was required for episodes of hypoglycaemia/hyperglycaemia but it is assumed
Analysis 1.12. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 12 Retinopathy.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 12 Retinopathy
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 2/16 2/17 100.0 % 1.06 [ 0.17, 6.67 ]
Total (95% CI) 16 17 100.0 % 1.06 [ 0.17, 6.67 ]
Total events: 2 (Lispro insulin), 2 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Lispro Favours Regular insulin
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Analysis 1.13. Comparison 1 Lispro versus regular insulin (Different insulin types within similar insulin
regimens), Outcome 13 Ventouse delivery.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 1 Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Outcome: 13 Ventouse delivery
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Persson 2002 3/16 1/17 100.0 % 3.19 [ 0.37, 27.58 ]
Total (95% CI) 16 17 100.0 % 3.19 [ 0.37, 27.58 ]
Total events: 3 (Lispro insulin), 1 (Regular insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours Lispro Favours Regular insulin
Analysis 2.1. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 1 Small-for-gestational age at
delivery.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 1 Small-for-gestational age at delivery
Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jovanovic-Peterson 1992 0/20 0/22 Not estimable
Total (95% CI) 20 22 Not estimable
Total events: 0 (Human insulin), 0 (Animal insulin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours human insulin Favours animal insulin
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Analysis 2.2. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 2 Preterm birth (< 37 weeks).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 2 Preterm birth (< 37 weeks)
Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jovanovic-Peterson 1992 3/20 0/22 100.0 % 7.67 [ 0.42, 139.83 ]
Total (95% CI) 20 22 100.0 % 7.67 [ 0.42, 139.83 ]
Total events: 3 (Human insulin), 0 (Animal insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours Human insulin Favours Animal insulin
Analysis 2.3. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 3 Birthweight centile (%).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 3 Birthweight centile (%)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 47.4 (23.5) 22 54.1 (32.2) 100.0 % -6.70 [ -23.64, 10.24 ]
Total (95% CI) 20 22 100.0 % -6.70 [ -23.64, 10.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours animal insulin Favours human insulin
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Analysis 2.4. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 4 Infant length (cm).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 4 Infant length (cm)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 47.5 (7.1) 22 50.8 (3.5) 100.0 % -3.30 [ -6.74, 0.14 ]
Total (95% CI) 20 22 100.0 % -3.30 [ -6.74, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours animal insulin Favours human insulin
Analysis 2.5. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 5 Skinfold thickness (mm).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 5 Skinfold thickness (mm)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 17.2 (12.8) 22 21.3 (17.4) 100.0 % -4.10 [ -13.28, 5.08 ]
Total (95% CI) 20 22 100.0 % -4.10 [ -13.28, 5.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 6 Body weight percentile (%).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 6 Body weight percentile (%)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 47.4 (23.5) 22 54.1 (32.5) 100.0 % -6.70 [ -23.74, 10.34 ]
Total (95% CI) 20 22 100.0 % -6.70 [ -23.74, 10.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 7 Head circumference (cm).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 7 Head circumference (cm)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 30.5 (9.9) 22 35.6 (2) 100.0 % -5.10 [ -9.52, -0.68 ]
Total (95% CI) 20 22 100.0 % -5.10 [ -9.52, -0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 8 Macrosomia.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 8 Macrosomia
Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jovanovic-Peterson 1992 (1) 0/20 2/22 100.0 % 0.22 [ 0.01, 4.30 ]
Total (95% CI) 20 22 100.0 % 0.22 [ 0.01, 4.30 ]
Total events: 0 (Human insulin), 2 (Animal insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 9 Insulin requirement during
pregnancy (U/kg/24 hour).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 9 Insulin requirement during pregnancy (U/kg/24 hour)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 1.01 (0.2) 22 1.34 (0.2) 100.0 % -0.33 [ -0.45, -0.21 ]
Total (95% CI) 20 22 100.0 % -0.33 [ -0.45, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.34 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 10 Birthweight (g).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 10 Birthweight (g)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 2727 (834) 22 3318 (727) 100.0 % -591.00 [ -1066.27, -115.73 ]
Total (95% CI) 20 22 100.0 % -591.00 [ -1066.27, -115.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 11 Infant fasting C-peptide level at 3
months (pmol/mL).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 11 Infant fasting C-peptide level at 3 months (pmol/mL)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 (1) 20 0.19 (0.09) 22 0.26 (0.12) 100.0 % -0.07 [ -0.13, -0.01 ]
Total (95% CI) 20 22 100.0 % -0.07 [ -0.13, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
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(1) Note the review has included a SD of 0.09 for the human insulin group. In the original paper by Jovanovic Peterson (1992) the figure entered for the SD in this group
was ’09’ with no decimal place.
Analysis 2.12. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 12 Infant C-peptide level 1 hour after
glucose-amino acid challenge at 3 months (pmol/mL).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 12 Infant C-peptide level 1 hour after glucose-amino acid challenge at 3 months (pmol/mL)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 0.21 (0.13) 22 0.32 (0.13) 100.0 % -0.11 [ -0.19, -0.03 ]
Total (95% CI) 20 22 100.0 % -0.11 [ -0.19, -0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 13 Infant glucose fasting level at 3
months (pmol/mL).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 13 Infant glucose fasting level at 3 months (pmol/mL)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 4.3 (0.7) 22 4.5 (0.7) 100.0 % -0.20 [ -0.62, 0.22 ]
Total (95% CI) 20 22 100.0 % -0.20 [ -0.62, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 14 Infant glucose level 1 hour after
glucose-amino acid challenge at 3 months (pmol/mL).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 14 Infant glucose level 1 hour after glucose-amino acid challenge at 3 months (pmol/mL)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 5.4 (0.9) 22 4.9 (0.9) 100.0 % 0.50 [ -0.04, 1.04 ]
Total (95% CI) 20 22 100.0 % 0.50 [ -0.04, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 15 Gestational age at delivery
(weeks).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 15 Gestational age at delivery (weeks)
Study or subgroup Human insulin Animal insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jovanovic-Peterson 1992 20 38.6 (9.4) 22 38.1 (1.9) 100.0 % 0.50 [ -3.70, 4.70 ]
Total (95% CI) 20 22 100.0 % 0.50 [ -3.70, 4.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Human insulin Favours Animal insulin
73Different insulin types and regimens for pregnant women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.16. Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Different insulin types within similar insulin regimens), Outcome 16 Maternal ketonuria.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Different insulin types within similar insulin regimens)
Outcome: 16 Maternal ketonuria
Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jovanovic-Peterson 1992 2/20 6/22 100.0 % 0.37 [ 0.08, 1.61 ]
Total (95% CI) 20 22 100.0 % 0.37 [ 0.08, 1.61 ]
Total events: 2 (Human insulin), 6 (Animal insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Different insulin regimens with similar insulin types used within the regimen), Outcome 1 Macrosomia.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Outcome: 1 Macrosomia
Study or subgroup Pre-mixed insulin Self-mixed insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schuster 1998 (1) 2/47 4/46 100.0 % 0.49 [ 0.09, 2.54 ]
Total (95% CI) 47 46 100.0 % 0.49 [ 0.09, 2.54 ]
Total events: 2 (Pre-mixed insulin), 4 (Self-mixed insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Different insulin regimens with similar insulin types used within the regimen), Outcome 2 Caesarean section.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Outcome: 2 Caesarean section
Study or subgroup Pre-mixed insulin Self-mixed insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schuster 1998 (1) 7/47 12/46 100.0 % 0.57 [ 0.25, 1.32 ]
Total (95% CI) 47 46 100.0 % 0.57 [ 0.25, 1.32 ]
Total events: 7 (Pre-mixed insulin), 12 (Self-mixed insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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(1) Caesarean section for cephalopelvic disproportion only
Analysis 3.3. Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Different insulin regimens with similar insulin types used within the regimen), Outcome 3 Antepartum
capillary glucose measurement (mg/dL), 2 hours postprandial (after lunch).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Outcome: 3 Antepartum capillary glucose measurement (mg/dL), 2 hours postprandial (after lunch)
Study or subgroup Pre-mixed insulin Self-mixed insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schuster 1998 (1) 5698 131.7641 (28.4168) 4520 143.02 (36.7172) 100.0 % -11.25 [ -12.55, -9.95 ]
Total (95% CI) 5698 4520 100.0 % -11.25 [ -12.55, -9.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 16.96 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Denominator for this outcome is the number of tests performed and not the number of women in each group
Analysis 3.4. Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Different insulin regimens with similar insulin types used within the regimen), Outcome 4 Postpartum
infection: endometritis.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Outcome: 4 Postpartum infection: endometritis
Study or subgroup Pre-mixed insulin Self-mixed insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schuster 1998 9/47 17/46 100.0 % 0.52 [ 0.26, 1.04 ]
Total (95% CI) 47 46 100.0 % 0.52 [ 0.26, 1.04 ]
Total events: 9 (Pre-mixed insulin), 17 (Self-mixed insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Different insulin regimens with similar insulin types used within the regimen), Outcome 5 Use of healthcare
resources (maternal hospital days).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Outcome: 5 Use of healthcare resources (maternal hospital days)
Study or subgroup Pre-mixed insulin Self-mixed insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schuster 1998 47 3.9106 (1.959) 47 4.41 (2.4726) 100.0 % -0.50 [ -1.40, 0.41 ]
Total (95% CI) 47 47 100.0 % -0.50 [ -1.40, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Different insulin regimens with similar insulin types used within the regimen), Outcome 6 Birthweight (g).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Outcome: 6 Birthweight (g)
Study or subgroup Pre-mixed insulin Self-mixed insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schuster 1998 3063.7872 (732.1138) 47 46 3180.35 (618.5966) 100.0 % -116.56 [ -391.81, 158.69 ]
Total (95% CI) 47 46 100.0 % -116.56 [ -391.81, 158.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Different insulin regimens with similar insulin types used within the regimen), Outcome 7 Compliance score.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Outcome: 7 Compliance score
Study or subgroup Pre-mixed insulin Self-mixed insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schuster 1998 (1) 24 3 (1.4) 25 3 (1.7) 100.0 % 0.0 [ -0.87, 0.87 ]
Total (95% CI) 24 25 100.0 % 0.0 [ -0.87, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe)
(Different insulin regimens with similar insulin types used within the regimen), Outcome 1 Macrosomia.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Different insulin regimens with similar insulin types used within the
regimen)
Outcome: 1 Macrosomia
Study or subgroup Novolin Pen Needle/Syringe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schuster 1998 (1) 1/45 5/48 100.0 % 0.21 [ 0.03, 1.76 ]
Total (95% CI) 45 48 100.0 % 0.21 [ 0.03, 1.76 ]
Total events: 1 (Novolin Pen), 5 (Needle/Syringe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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(1) birthweight > 4000g
Analysis 4.2. Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe)
(Different insulin regimens with similar insulin types used within the regimen), Outcome 2 Caesarean section.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Different insulin regimens with similar insulin types used within the
regimen)
Outcome: 2 Caesarean section
Study or subgroup Novolin Pen Needle/Syringe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schuster 1998 (1) 5/45 14/48 100.0 % 0.38 [ 0.15, 0.97 ]
Total (95% CI) 45 48 100.0 % 0.38 [ 0.15, 0.97 ]
Total events: 5 (Novolin Pen), 14 (Needle/Syringe)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle
(syringe) (Different insulin regimens with similar insulin types used within the regimen), Outcome 3
Antepartum capillary glucose measurement (mg/dL) 2 hours postprandial (after lunch).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Different insulin regimens with similar insulin types used within the
regimen)
Outcome: 3 Antepartum capillary glucose measurement (mg/dL) 2 hours postprandial (after lunch)
Study or subgroup Novolin Pen Needle/Syringe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schuster 1998 (1) 5425 133.3514 (29.834) 4793 140.58 (35.5355) 100.0 % -7.23 [ -8.51, -5.95 ]
Total (95% CI) 5425 4793 100.0 % -7.23 [ -8.51, -5.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.05 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Denominator for this outcome is the number of tests performed and not the number of women in each group
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Analysis 4.4. Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle
(syringe) (Different insulin regimens with similar insulin types used within the regimen), Outcome 4
Postpartum infection: endometritis.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Different insulin regimens with similar insulin types used within the
regimen)
Outcome: 4 Postpartum infection: endometritis
Study or subgroup Novolin Pen Needle/Syringe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schuster 1998 9/45 17/48 100.0 % 0.56 [ 0.28, 1.14 ]
Total (95% CI) 45 48 100.0 % 0.56 [ 0.28, 1.14 ]
Total events: 9 (Novolin Pen), 17 (Needle/Syringe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle
(syringe) (Different insulin regimens with similar insulin types used within the regimen), Outcome 5 Use of
healthcare resources (maternal hospital days).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Different insulin regimens with similar insulin types used within the
regimen)
Outcome: 5 Use of healthcare resources (maternal hospital days)
Study or subgroup Novolin Pen Needle/Syringe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schuster 1998 45 3.84 (1.8143) 48 4.4 (2.5406) 100.0 % -0.56 [ -1.45, 0.33 ]
Total (95% CI) 45 48 100.0 % -0.56 [ -1.45, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe)
(Different insulin regimens with similar insulin types used within the regimen), Outcome 6 Birthweight (g).
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Different insulin regimens with similar insulin types used within the
regimen)
Outcome: 6 Birthweight (g)
Study or subgroup Novolin Pen Needle/Syringe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schuster 1998 3037.6444 (713.4101) 45 48 3200 (638.8987) 100.0 % -162.36 [ -438.25, 113.53 ]
Total (95% CI) 45 48 100.0 % -162.36 [ -438.25, 113.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe)
(Different insulin regimens with similar insulin types used within the regimen), Outcome 7 Compliance score.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Different insulin regimens with similar insulin types used within the
regimen)
Outcome: 7 Compliance score
Study or subgroup Novolin Pen Needle/Syringe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schuster 1998 (1) 45 2.7889 (1.5218) 48 3 (1.5441) 100.0 % -0.21 [ -0.83, 0.41 ]
Total (95% CI) 45 48 100.0 % -0.21 [ -0.83, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Syringe Favours Pen
(1) score ranges from 1 to 5, 1 = best, 5 = worst
Analysis 5.1. Comparison 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Different
insulin types within similar insulin regimens), Outcome 1 A1c (%) third trimester visit.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Different insulin types within similar insulin regimens)
Outcome: 1 A1c (%) third trimester visit
Study or subgroup Aspart insulin Human insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mathiesen 2007 (1) 113 6 (0.7) 110 6.1 (0.7) 100.0 % -0.10 [ -0.28, 0.08 ]
Total (95% CI) 113 110 100.0 % -0.10 [ -0.28, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours insulin Aspart Favours Human insulin
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(1) which way round should the forest plot labels go? Is high % A1C better or worse?
Analysis 5.2. Comparison 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Different
insulin types within similar insulin regimens), Outcome 2 Average plasma glucose (mmol/L) third trimester
visit.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Different insulin types within similar insulin regimens)
Outcome: 2 Average plasma glucose (mmol/L) third trimester visit
Study or subgroup Aspart insulin Human insulin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mathiesen 2007 113 6.2 (1.2) 110 6.4 (1.3) 100.0 % -0.20 [ -0.53, 0.13 ]
Total (95% CI) 113 110 100.0 % -0.20 [ -0.53, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Aspart insulin Favours Human insulin
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Analysis 5.3. Comparison 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Different
insulin types within similar insulin regimens), Outcome 3 Maternal hypoglycaemic episodes.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Different insulin types within similar insulin regimens)
Outcome: 3 Maternal hypoglycaemic episodes
Study or subgroup Aspart insulin Human insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mathiesen 2007 108/113 99/110 100.0 % 1.06 [ 0.99, 1.14 ]
Total (95% CI) 113 110 100.0 % 1.06 [ 0.99, 1.14 ]
Total events: 108 (Aspart insulin), 99 (Human insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours insulin Aspart Favours Human insulin
Analysis 6.1. Comparison 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin
Aspart (Different insulin types within similar insulin regimens), Outcome 1 Major congenital malformation.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Different insulin types within similar insulin regimens)
Outcome: 1 Major congenital malformation
Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mathiesen 2012 (1) 3/79 1/83 100.0 % 3.15 [ 0.33, 29.67 ]
Total (95% CI) 79 83 100.0 % 3.15 [ 0.33, 29.67 ]
Total events: 3 (Detemir insulin), 1 (NPH insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours insulin Detemir Favours NPH
(1) blinded outcome assessment
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Analysis 6.2. Comparison 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin
Aspart (Different insulin types within similar insulin regimens), Outcome 2 Major congenital malformation.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Different insulin types within similar insulin regimens)
Outcome: 2 Major congenital malformation
Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mathiesen 2012 (1) 2/79 1/83 100.0 % 2.10 [ 0.19, 22.72 ]
Total (95% CI) 79 83 100.0 % 2.10 [ 0.19, 22.72 ]
Total events: 2 (Detemir insulin), 1 (NPH insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours insulin Detemir Favours NPH
(1) unblinded outcome assessment
Analysis 6.3. Comparison 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin
Aspart (Different insulin types within similar insulin regimens), Outcome 3 Minor congenital malformation.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Different insulin types within similar insulin regimens)
Outcome: 3 Minor congenital malformation
Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mathiesen 2012 (1) 0/79 1/83 100.0 % 0.35 [ 0.01, 8.47 ]
Total (95% CI) 79 83 100.0 % 0.35 [ 0.01, 8.47 ]
Total events: 0 (Detemir insulin), 1 (NPH insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours insulin Detemir Favours NPH
(1) blinded outcome assessment
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Analysis 6.4. Comparison 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin
Aspart (Different insulin types within similar insulin regimens), Outcome 4 Minor congenital malformation.
Review: Different insulin types and regimens for pregnant women with pre-existing diabetes
Comparison: 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Different insulin types within similar insulin regimens)
Outcome: 4 Minor congenital malformation
Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mathiesen 2012 (1) 3/79 3/83 100.0 % 1.05 [ 0.22, 5.05 ]
Total (95% CI) 79 83 100.0 % 1.05 [ 0.22, 5.05 ]
Total events: 3 (Detemir insulin), 3 (NPH insulin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours insulin Detemir Favours NPH
(1) unblinded outcome assessment
A P P E N D I C E S
Appendix 1. Search terms for ClinicalTrials.gov and the WHO International Clinical Trials Registry
Platform
type 1 diabetes AND pregnancy
type 2 diabetes AND pregnancy
insulin AND diabetes AND pregnancy
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. HW has been added as an author.
2. We added additional outcomes and labelled these as ’not prespecified outcomes’. For infants, these included: birthweight (g);
infant fasting C-peptide level at three months (pmol/mL); infant C-peptide level one hour after glucose-amino acid challenge at three
months (pmol/mL)); infant fasting glucose level at three months (pmol/mL); infant glucose level one hour after glucose-amino acid
challenge at three months (pmol/mL), and gestational age at delivery. Additional maternal outcomes included: ventouse delivery;
maternal ketonuria, and a maternal compliance with treatment score (1 = best, 5 = worst compliance).
3. We have reworded other outcomes to be in line with the list of core outcomes for diabetes in pregnancy (use of healthcare
resources now includes maternal hospital days, pre-eclampsia includes pregnancy-induced hypertension, neonatal adiposity includes
body weight percentile).
4. SON and HW performed the screening for eligibility, data extraction, and risk of bias for the included studies
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Diabetes Mellitus, Type 1 [∗drug therapy]; Diabetes Mellitus, Type 2 [∗drug therapy]; Hypoglycemic Agents [administration & dosage;
∗therapeutic use]; Insulin [administration & dosage; ∗therapeutic use]; Insulin Aspart [therapeutic use]; Insulin Detemir [therapeutic
use]; Insulin Lispro [therapeutic use]; Pregnancy Complications [∗drug therapy]; Pregnancy in Diabetics [∗drug therapy]
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Female; Humans; Pregnancy
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